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One of a large number of mutant mice used in immunological research, the 
"motheaten" mouse was the first model of a specific protein tyrosine phosphatase 
deficiency. Mice carrying one of two allelic mutations at the "motheaten" locus have 
severe systemic autoimmunity and immune dysfunction as a result of mutations in the 
hematopoietic-cell phosphatase (Hcph) gene, which encodes the protein tyrosine 
phosphatase SHP-1. Studies using "motheaten" (me/me) and "viable motheaten" 
(mev/mev) mice have increased the understanding of numerous signaling pathways in 
immune and hematopoietic cells. A number of studies on SHP-1 function in normal and 
pathologic states are described here. 
Homozygous mev/mev mice have an increased percentage of autoantibody 
associated B-1 B-cells that express the cell surface glycoprotein CD5. To investigate the 
hypothesis that absence of CD5 in mev/mev mice will result in decreased systemic 
autoimmunity, we created a stock of ~~5""me'/rne' mice. These mice have a longer 
lifespan than mev/mev mice, associated with reduced pulmonary inflammatory disease, 
splenic macrophage numbers, and serum IgM levels. However, autoantibodies against 
dsDNA and histone proteins were not significantly reduced. These studies suggest that 
CD5 expression is not required for autoantibody production, but otherwise indicate a role 
for CD5 in the development of irnrnunopathologic lesions in mev/mev mice. 
Dysregulated macrophage populations in mev/mev mice presumably have 
secondary effects on other cell types. To examine these effects, as well as the primary 
results of SHP-1 deficiency in macrophages, we developed a stock of mice transgenic for 
a dominant-negative form of SHP-1, under control of a macrophage specific promoter. 
The catalytically inactive dominant-negative protein should occupy SH2 binding sites, 
blocking the recruitment of functional wild-type SHP-1. 
SHP- 1 plays a putative role in oncogenesis. To substantiate this role, we have 
monitored tumor development in aged +/me and +/mev mice. Preliminary studies do not 
support the hypothesis that a spontaneous chondroblastic osteosarcoma that occurred in 
an aging +/mev mouse was caused by loss of SHP- 1 expression. Nonetheless, we 
describe the transplantable cell-line derived from this tumor, which mimics the process of 
endochondral ossification in vivo and is a potentially valuable model for studies of 
osteosarcoma and bone biology. 
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Chapter 1 
THE MOLECULAR BASES OF SPONTANEOUS IMMUNOLOGICAL 
MUTATIONS IN THE MOUSE AND THEIR HOMOLOGOUS HUMAN 
DISEASES ' 
Introduction 
Spontaneous genetic mutations that disrupt development or regulation of the 
immune system in inbred mouse strains provide unique models for the study of immune 
deficiency and autoimmune diseases of humans. While these mouse mutations have been 
widely utilized to increase our understanding of the immune system in normal and 
pathological states, recent determination of the molecular bases of many of these 
mutations has provided even deeper insight into the underlying biology and biochemistry 
of the mammalian immune system. A number of the mouse genes disrupted by 
spontaneous mutation have human homologues, and mutations in many of the human 
genes result in immunological diseases. In these cases, immunological mutations in mice 
provide an especially valuable resource to study mechanisms of disease and to investigate 
experimental interventions that may lead to treatments for the human disease. 
In recent years, advances in transgenic and gene targeting technology have 
allowed generation of mice with genetic alterations specifically targeted to selected genes 
or regions of genes, allowing focused analysis of their products and functions. While 
these technologies have become powerful tools for scientific research, they commonly 
rely on identification and cloning of a gene prior to creating a targeted mutation of that 
gene. While targeted mutation of a specific gene often results in an imperceptible or 
unexpected phenotype, spontaneous mutants are selected by discemable phenotypes of 
interest. Investigation into the genetic basis of many of these spontaneous mutations has 
led to the identification of previously unknown, novel genes. 
The intent of this review is not to provide exhaustive detail about the phenotypes 
of mutant mice. The phenotypes of many of these mutants have been reviewed 
previously (I), and references to available reviews specific to each mutant will be 
provided. This review has been written as an overview of spontaneous mouse mutations 
resulting in immunodeficient or autoimmune phenotypes that have been defined at the 
molecular level (summarized in Table 1.1). Human diseases with homology to these 
mouse mutations are discussed, and the uses of these mice in research on human disease 
and immunobiological function are also discussed (summarized in Table 1.2). 
Genetic nomenclature can be complex. Gene symbols are changed as loci are 
identified at the molecular level and gene families are determined. The current approved 
symbol for each mouse gene is provided in the heading for the individual mutations, as 
well as in Table 1.1. The symbol for the homologous human gene is provided in Table 
1.2, and is included in the text. General background of nomenclature changes is provided 
in the text, and the most commonly known name for each gene and mutation is used in 
subsequent discussion. 
Based on: Joliat MJ, Shultz LD. 2001. The molecular bases of spontaneous immunological mutations in 
the mouse and their homologous human diseases. (Review) Clin. Immunol. lOl(3): 1 13-129. 
Table 1.1. The molecular bases of spontaneous immunological mutations in the mouse. 
Allele Name 
(Original Symbol) 
severe combined 
immunodeficiency 
(scid) 
Gene 
Symbol 
Prkdc 
Gene Name Mouse 
Chr 
16 
Phenotype 
DNA activated 
protein kinase, 
catalytic subunit 
forkhead box nl 
(forkheadwinged 
helix family of 
transcription factors) 
Severe immune deficiency 
caused by absence of both B and 
T cells, radiosensitivity 
Hairless, athymic, T-cell 
deficiency 
nude (nu) Foxnl 
scurfy (sj) forkhead box P3 
(forkheadwinged 
helix family of 
transcription factors) 
Thrombocytopenia, increased 
numbers of CD4+/CD8- T 
lymphocytes, extensive multi- 
organ infiltration, and elevation 
of numerous cytokines 
Severe immune deficiency, 
autoimmunity, x-ray resistance 
motheaten (me), Hcph hematopoietic cell 
phosphatase 
lymphoproliferation 
(lpr) 
tumor necrosis family 
receptor superfamily, 
member 6 
tumor necrosis factor 
superfamily, member 
6 
Lymphadenopathy, 
autoimmunity 
generalized 
lymphoproliferative 
disease (gld) 
Lymphadenopathy. 
autoimmunity 
dominant spotting 
(w) 
Kit kit oncogene (stem 
cell factor receptor) 
Defects in pigment forming cells, 
RBC's, mast cells and progenitor 
cells, impaired resistance to 
parasitic infection 
Severe macrocytic anemia, mast 
cell deficiency 
steel (sl) kit ligand (stem cell 
factor) 
X-linked 
immunodeficiency 
(xi4 
Btk Bruton's 
agammaglobulinemia 
tyrosine kinase 
Defective immune response to 
type 11 thymus-independent (TI- 
11) antigens, impaired immune 
response to some thymus- 
dependent (TD) antigens, and 
impaired lymphocyte response to 
B-cell mitogens 
alymphoplasia (aly) mitogen-activated 
protein kinase kinase 
kinase 14 
Absence of lymph nodes and 
Peyer's patches 
Allele Name Gene 
Symbol 
Lyst 
Gene Name Mouse 
Chr 
13 
Phenotype 
lysosomal trafficking Abnormal giant lysosomal 
granules in granule containing 
cells, defective granulocyte 
activity, NK cell deficiency, 
platelet storage pool deficiency 
regulator 
osteopetrosis (op) colony stimulating 
factor 1 
(macrophage) 
Osteoclast defects, macrophage 
deficiency, monocytopenia, 
defective bone remodeling 
defective 
lipopolysaccharide 
response (48) 
toll-like receptor 4 Defective response to bacterial 
endotoxin. Increased 
susceptibility to Gram-negative 
infection. 
microphthalmia (mi) microphthalmia 
associated 
transcription factor 
Developmental defects in 
melanocytes, osteoclasts and 
mast cells 
wasted (wst) eukaryotic translation 
elongation factor 1 
alpha 2 
Tremor, progressive paralysis, 
lymphoid hypoplasia, death by 
30 days of age 
hairless (hr) hairless High incidence of early onset 
leukemia, low cellular immune 
response, deficiency of splenic 
TH cells. 
Table 1.2. Human homologous diseases and uses of mouse models in the study of human 
disease and irnrnunologica~function. 
Mouse Mutation 
severe combined 
immunodeficiency 
nude 
scurfy 
motheaten 
lymphoproliferation 
generalized 
lymphoproliferative 
disease 
dominant spotting 
steel 
X-linked 
immunodeficiency 
Human 
Gene 
BTK 
( C h  X )  
Human Disease Homologues and Uses in Research on Human 
Diseases 
Mutations in the human PRKDC gene have not been found associated 
with human SCID or any other disease. However, scid mice are 
widely used as hosts for normal and malignant human cells. They are 
also used as a model to study combined immune deficiency in 
humans and as a tool to decipher the normal biological role of DNA- 
PK. 
A mutation in this gene has been found in a family in Italy resulting 
in immune deficiency with absence of thymus and hair (OMIM 
601705). These mice also serve as hosts for human solid tumors. 
Mutations in FOXP3 are associated with the X-linked syndrome of 
immunodysregulation, polyendocrinopathy and enteropathy (IF'EX) 
(OMIM 304930). May be used to study autoimmune disease 
development and molecular mechanisms involved in T cell 
regulation. 
No diseases are known to result from heritable mutations in PTPN6. 
Somatic mutations in this gene and defective gene expression have 
been associated with myeloid leukemia, T-cell lymphoma, 
polycythemia Vera and breast cancers. Motheaten mice are also used 
to study the normal function of the SHP-1 phosphatase in the immune 
system. 
Mutations in TNFRSF6 and TNFSF6 are associated with autoimmune 
lymphoproliferative syndrome 1 A (ALPS 1 A-also called Canale- 
Smith syndrome) and ALPSIB, respectively (OMIM 601859). 
Spontaneous somatic mutations in TNFRSF6 have been found in 
cases of T-cell leukemia, multiple myeloma and non-Hodgkin's 
lymphoma. Study of these mice can also provide insights into the 
death receptor mediated system and its role in human disease. 
Germ line mutations in KIT have been found to cause human 
piebaldism (OMIM 172800). Somatic mutations, many of which 
cause constitutive activation of KIT, have been associated with mast 
cell neoplasia, cutaneous mastocytosis and tumors of the 
gastrointestinal stroma in humans. 
Bruton's X-linked agamrnaglobulinemia (XLA) (OMIM 300300) is 
caused by a variety of mutations in BTK. Mice with the xid mutation 
are also valuable tools for investigation of B cell-lineage development 
and signaling. 
Mouse Mutation Human 
Gene 
Human Disease Homologues and Uses in Research on Human 
Diseases 
alymphoplasia 
beige 
osteopetrosis 
defective 
lipopolysaccharide 
response 
microphthalmia 
wasted 
hairless 
There are no known human diseases caused by mutations in 
MAP3K14. Mice homozygous for the aly mutation are valuable tools 
in the study of inflammatory processes involving NF-K-B induction. 
The bg mouse is the homologue of human Chediak-Higashi syndrome 
(OMIM 214500). Studies using the bg mouse may contribute to the 
understanding of the accelerated phase of Chediak-Higashi syndrome 
by helping to reveal the role of CTLA4 in T-cell regulation and 
lymphoproliferation. 
Osteopetrosis in humans has not been found associated with 
mutations in CSFI.  However, op mice are a valuable resource in the 
study of osteopetrotic diseases and have contributed significantly to 
the understanding of normal bone biology 
Mutations in TLR4 have been associated with reduced response to 
inhaled LPS in humans. Study of mice carrying the L ~ ~ C '  allele may 
lead to new approaches in the treatment of septic shock, endotoxin 
induced airway inflammation and other endotoxin mediated diseases. 
Mutations in MITF are associated with Waardenburg Syndrome type 
2 (WS2) (OMIM 1935 10) and Tietz syndrome (OMIM 103500). 
Studies of mi mice can provide insights into mechanisms of 
melanocyte signaling and development. 
There are no human diseases known to be related to mutations in 
EEFIA2. Studies of wst mice have revealed mechanisms in the 
developmental regulation of protein translation. 
Mutations in the human HR gene are associated with congenital 
atrechia with papules (OMIM 209500). 
S~ontaneous Immunological Mutations in the Mouse 
Severe combined immune deficiency (~rkdc"'~) 
In 1983, Bosma et al. (2) reported a mutation (scid) in a colony of C.B-17 mice 
whose phenotype resembled human severe combined immune deficiency (SCID). 
Homozygosity for the scid mutation results in a deficiency of T and B lymphocytes with 
accompanying hypogammaglobulinemia and absence of both humoral and cell-mediated 
immune function (reviewed in (3)). Although C.B-17-scid mice have defects in adaptive 
immunity, many aspects of their innate immune function are unaltered ((4) and included 
references). C.B-17-scid mice have been widely used as hosts for human 
hematolymphoid cells, but intact innate immunity prevented long term survival of these 
cells. Backcrossing of the scid mutation onto the NODJLt strain background, which 
confers multiple defects in innate immunity, provided a scid mouse model in which 
survival of transplanted human cells was significantly increased (4). NODILtSz-scid 
mice are now a commonly used host for normal as well as malignant human 
hematolymphoid cells in many areas of research. 
The scid mutation results in failure of V@)J recombination (5-8) and also causes 
a defect in DNA double-strand break @SB) repair (9, lo), which leads to increased 
radiosensitivity (1 I). These observations preceded the discovery that the mutation 
causing the scid phenotype was within the gene encoding the catalytic subunit of a DNA- 
dependent protein kinase (DNA-PK,) (12), now given the formal gene symbol Prkdc. 
DNA-PK is a serinelthreonine protein kinase composed of the catalytic subunit as well as 
a regulatory component, the Ku701Ku80 heterodimer, which binds DNA ends. DNA-PK 
plays a role in non-homologous end joining and is essential to the proper functioning of 
the mechanisms of DSB repair and V@)J recombination as well as a number of other 
processes (for review, see (13)). 
Mutations in DNA-PKcs have been associated with SCID in both Arabian foals 
(14) and Jack Russell terriers (15). However, of the many severe combined immune 
deficiencies known in humans, none have yet been associated with mutations at the 
human PRKDC locus. The severity of V@)J recombination defects in animals with 
DNA-PKcs mutations correlates with the normal enzymatic activity of DNA-PK in the 
species (15). Genetic DNA-PKcs deficiency causes a severe V@)J recombination deficit 
in horses, which have relatively high normal DNA-PK activity. The level of DNA-PK 
activity in humans is many times higher than that of horses, suggesting that humans may 
have a profoundly severe phenotype as a result of a genetic DNA-PKcs mutation. It is 
possible that a gennline mutation in PRKDC would be lethal (15). DNA-PKcs defects in 
mice, in which DNA-PK activity is relatively low, cause a less severe V@)J 
recombination deficit than in humans or horses. Nonetheless, in addition to being 
important tools in hematology, cancer and AIDS research, mice homozygous for the scid 
mutation are a valuable models for the study of combined immune deficiency and for 
investigation of the normal biological role of DNA-PK in non-homologous end joining. 
Analysis of the differential requirement for DNA-PKcs between species may reveal 
important insights into the mechanisms of V@)J recombination and DSB repair. 
Nude (Fomzl ""l 
The nude (nu) mutation was first reported in 1966 as an autosomal recessive 
mutation that resulted in hairlessness and failure to thrive (16). In 1968, Pantelouris (17) 
observed that nu mice were congenitally athymic and exhibited leukopenia. Extensive 
studies in many laboratories have utilized these T-cell-deficient mice to examine the roles 
of T-cells in host defense against pathogens and in immune responses to various antigens. 
The mouse nu mutation is within a gene encoding a forkheadwinged helix 
transcription factor (18). Members of this family of transcription factors are involved in 
gene regulation during embryological development and cell differentiation (19). The 
disrupted gene responsible for the nu phenotype was originally designated as whn 
(winged-helix-nude), but was renamed Hfhl l  and, more recently, Foxnl to comply with 
unified nomenclature designation for forkheadwinged helix transcription factors (20). A 
second mutation at the nude locus, named 'streaker' (nu"?, occurred in an inbred colony 
of AKRfJ mice (21,22). The phenotype of these mice resembles that of nu mice and the 
symbol for the mutation has been designated Foxnl""". Mutations in homologous genes 
have also been reported in rats (23) and guinea pigs (24). Foxnl is expressed specifically 
in the epithelial cells of the thymus and skin (18). Thus, the T cell deficiency seen in nu 
mice is a result of a defective thymic microenvironment rather than intrinsic defects in T 
cell progenitors. 
Mice carrying the nu mutation are valuable tools for cancer research since they 
serve as experimental hosts for certain human neoplasms (25) (for review, see (26)). 
However, mice with the scid mutation are now recognized as a more appropriate model 
for studying human tumor biology than nu mice. Nude mice lack mature T cells, but they 
do have functional B cells and circulating immunoglobulin, as well as high levels of NK 
cell activity, which can prevent the growth of certain tumors. Many tumors, particularly 
those of hematopoietic origin, grow better in scid mice, which lack both B and T cells. 
Some solid tumors, however, such as mammary cancers, appear to grow equally well in 
nu and scid mice, and thus nu mice are still a commonly used model in studies of solid 
tumor biology and experimental therapy (27,28). 
The nu mouse was originally proposed as a model for DiGeorge syndrome in 
humans, but this mutant lacks certain characteristics of DiGeorge syndrome, such as 
parathyroid hypoplasia and cardiac anomalies. DiGeorge syndrome has since been found 
to be due to deletion of a region of human chromosome 22q11, which contains a number 
of genes that may be responsible for the syndrome (29). Recently, a nonsense mutation 
in exon 5 of the homologous human gene, termed winged helix nude (WHN), was 
reported in a family in Italy (30,3 1). Two sisters presented with a phenotype of impaired 
T-cell function, alopecia, nail dystrophy and absence of a thymic shadow. This rare 
condition is an interesting example of how a mutation in a gene not expressed in 
hematopoietic cells can result in an immunodeficiency disease in humans. 
Scurfy (FoxpYf'l 
The scurfy (sf) mutation was first reported in 1959 (32) and further described in the early 
1990's (33-35). Scurfy is an X-linked mutation characterized by anemia, 
thrombocytopenia and a lymphoproliferative disorder that results in splenomegaly, 
hepatomegaly, and enlarged lymph nodes. These pathologic changes are accompanied by 
diarrhea, exfoliative dermatitis and runting (33,34). Hernizygous males have an average 
lifespan of 24 days (33). The lymphoproliferative disease in sf mice is mediated by 
CD4TD8- T lymphocytes (36,37), and involves over-expression of a variety of cytokine 
genes (38,39). 
The sf mutation was at one time proposed to be a model for human Wiskott- 
Aldrich syndrome (WAS) ( 3 9 ,  because sf and WAS map to homologous regions of the 
mouse and human X chromosomes (40,41). However, sf has recently been identified as 
a mutation in the Foxp3 gene, which encodes a novel forkheadwinged helix transcription 
factor called scurfin (42). Although the phenotype of sf mice clearly demonstrates the 
requirement of the scurfin protein for normal T cell function, the precise role of this 
transcription factor and the mechanisms that regulate its expression have not yet been 
elucidated. 
The growing family of forkheadwinged helix transcription factors contains many 
members that are highly conserved between species (19,20,43). The human homologue 
of the mouse scurfin gene has been identified. Mutations in this gene, FOXP3, have been 
found associated with a human X-linked syndrome of immune dysregulation, 
polyendocrinopathy and enteropathy called IPEX (44-46) (for review, see (47)). IPEX is 
a frequently fatal disease of childhood that shares many of the phenotypic characteristics 
of the sf mouse (48). Patients suffer from insulin-dependent diabetes mellitus (IDDM), 
hypothyroidism, immune thrombocytopenia, and eczema. There are currently no 
treatments shown to have long-term success in IPEX patients (49). The mouse sf 
mutation provides a valuable model for the study of this severe human autoimmune 
disease and may assist in the development of immunological therapy. Studies of these 
mice may also offer further insights into the molecular mechanisms involved in the 
regulation of T cell function in the normal human immune system. 
Lymphoproliferation !~nfr@5'~? and generalized lymphoproliferative disease ( ~ n f ~ f 6 ~ ' ~ )  
Mice homozygous for the lymphoproliferation (Ipr) and generalized 
lymphoproliferative disease (gld) mutations share nearly identical phenotypes, 
characterized by systemic autoimmunity and massive T-lymphoid hyperplasia. 
Accompanying polyclonal B cell activation results in hypergammaglobulinemia and high 
levels of autoantibodies against a variety of autoantigens in both Ipr and gld mice, 
contributing to the development of immune complex glomerulonephritis. Both T- and B- 
lymphocyte populations of Ipr and gld mice are deficient in their responses to exogenous 
immune stimuli (50, 51) (for review, see (52)). 
The Ipr mutation arose during the development of the MRLMpJ inbred strain, 
and was first reported in 1978 (50,53) as a model of systemic lupus erythematosus 
(SLE). MRL wild type mice do not exhibit lymphoproliferation, but do develop SLE-like 
symptoms at about two years of age, leading to the original hypothesis that the Ipr 
mutation may act only to accelerate the development of autoimmune disease in strains 
already prone to autoimmunity. Although transfer of this mutation to a variety of inbred 
backgrounds lacking a predisposition to autoimmunity results in lymphadenopathy and 
autoimmunity, the severity of disease varies depending on the genetic background of the 
strain (54). MRWMpJ mice are the most severely affected by the Ipr mutation; 
homozygotes die by 6 months of age. 
The observation that neonatal thymectomy significantly reduces autoimmune 
disease and lymphadenopathy in Ipr mice (55) was followed by the discovery that the Ipr 
mutation caused the aberrant expansion of an abnormal population of CD4- CD8- (double 
negative, DN) T cells (56). Approximately a decade later, the lpr mutation was found to 
be in the gene encoding the Fas antigen (also called CD95 or APO- I), a widely expressed 
cell surface protein that mediates apoptosis and is involved in the negative selection of 
autoreactive T cells in the thymus (57, 58). Fas shares structural homology with the 
tumor necrosis factor receptor family, and the gene has since been renamed 'Tumor 
necrosis factor receptor superfamily, member 6' or Tnfrsfs. A new allele at the lpr locus 
was reported in 1990, termed lpf (59), resulting in a phenotype similar to the lpr 
mutation. The lpr mutation results in the absence of cell surface Fas, while the lpfg 
mutation results in expression of a non-functional receptor (60). The gld mutation, which 
produces a phenotype similar to lpr, occurred in a colony of C3HlHeJ inbred mice (5 1, 
61). The gld mutation was found to be the result of a point mutation in the gene encoding 
the ligand for Fas (Fasl, CD95L) (62), now termed 'tumor necrosis factor superfamily 
member 6' (Tnfsm. 
Fas mediated apoptosis is crucial to the proper development and function of the 
immune system (see review (63)). Studies of lpr and gld mice have provided valuable 
insights into the death receptor mediated system and its role in human disease (for review 
see (64)). In humans, mutations affecting both Fas (TNFRSF6) and Fas ligand (TNFSF6) 
are associated with Autoimmune Lymphoproliferative Syndrome (ALPS), a childhood 
dsease characterized by lymphadenopathy and autoimmunity. Mutations of TNFRSF6 
are commonly associated with a form of ALPS called ALPSlA, also known as Canale- 
Smith syndrome (65-68). A mutation of TNFSF6 was discovered in a screening of SLE 
patients (69). This patient had lymphoproliferative disease as well as symptoms of SLE, 
and the case was later designated as an alternative form of ALPS, called ALPSlB (70). 
Somatic mutations of Fas have also been associated with a number of human 
malignancies including T-cell leukemia (71,72), multiple myeloma (73), and non- 
Hodgkin's lymphoma (74) (for review, see (75)). 
Dominant white spotting  it^) and steel { ~ i t l ~ ' )  
Mutations at the dominant white spotting (W) (76,77) and steel (Sl) (78) loci 
affect the development of hematopoietic precursor cells, mast cells, neural crest-derived 
melanocytes and germ cells. Consequences of these developmental abnormalities include 
macrocytic anemia, mast cell deficiency, pigmentation abnormalities and infertility 
(reviewed in (79)). There are a number of alleles at both the W and Sl loci, resulting in 
diverse phenotypic effects that vary in severity from embryonic lethality to mild anemia 
with survival to adulthood (79-81) 
Although the phenotypes of Wand Sl mutant mice are similar, numerous early 
studies indicated that the sl mutation affected the extracellular microenvironment, while 
the W mutation was within a gene expressed by the affected stem cells themselves (82- 
86). The genes disrupted by these two mutations were found to encode a growth 
factorlreceptor pair essential to a variety of developmental processes. The W mutation 
affects the Kit proto-oncogene (also known as c-Kit), which encodes a transmembrane 
receptor tyrosine kinase, KIT. (87, 88). The steel mutation affects the gene encoding 
stem cell factor (SCF) (also called mast cell growth factor, kit-ligand or steel factor, 
current approved gene symbol: Kitl), which is the ligand for KIT (89-92) (see review 
(93)). 
KIT is expressed at various levels on a wide variety of cell types. SCF (Kitl) is 
expressed on stromal cells, fibroblasts and endothelial cells, and is found at low levels in 
the circulation. This growth factor/receptor system has been implicated in a wide variety 
of processes, from promotion of hematopoietic cell survival and proliferation to 
mediation of cell migration and adhesion (for review, see (94-97). 
In humans, heritable mutations in the homologue of the mouse Kit gene, KIT, 
have been found to cause piebaldism (98,99), a genetic disorder resulting in patches of 
white skin and hair due to a disorder in melanocyte development. In contrast to the W 
mouse, individuals affected by piebaldism exhibit no apparent defects in mast cell 
function nor do they develop anemia as a consequence of the KIT mutation. 
Spontaneous, non-familial mutations in the KIT gene have been found in cases of human 
mast cell neoplasia and cutaneous mastocytosis (100, 101), as well as in tumors of the 
gastrointestinal stroma (102, 103). These mutations often cause constitutive activation of 
KIT (for a review of KIT activating mutations, see (104)). No mutations have been 
found in KITLG, the human homologue of the mouse stem cell factor gene. 
X-linked immune deficiency ( ~ t k " ~ )  
X-linked agammaglobulinemia (XLA) in humans was first reported as a primary 
immunodeficiency disease in 1959 (105). XLA patients have severely decreased levels 
of mature B lymphocytes, dramatically reduced levels of serum immunoglobulin (Ig) and 
are highly susceptible to bacterial infections (105, 106). Many years later, the X-linked 
immune deficiency (xid) mutation was observed in the CBAIN mouse strain, resulting in 
a disease with characteristics similar to, but less severe than human XLA (107-1 11). 
Peripheral B cells in xid mice are moderately reduced in number, and those present 
display a primarily immature phenotype. Mouse xid is also characterized by impaired 
signaling through a variety of B-cell surface receptors, absence of peritoneal B-1 cells, 
reduced levels of serum IgM and IgG3 and failure to respond to type II thymus- 
independent (TI-II) antigens (reviewed in (1 12)). 
The mutations causing both the human and mouse chseases lie within the 
respective genes encoding a cytoplasmic protein-tyrosine lunase, coined Bruton's 
agarnmaglobulinemia tyrosine kinase (Btk) (1 13-1 16). Btk is a member of a growing 
family of homologous tyrosine kinases (reviewed in (1 17, 118)). Although Btk appears 
to function primarily in the B-cell lineage, in development and expansion of early B cells 
and in survival and activation of mature B cells, this tyrosine lunase is expressed in 
erythroid progenitors and monomyeloid cells in adchtion to B cells (1 13, 114). Btk is not, 
however, expressed on T or NK cells. Mouse xid results from a specific rnissense 
mutation in Btk affecting the pleckstrin homology (PH) domain of the BTK protein (1 15, 
116). 
Human XLA has been found associated with an extensive variety of BTK 
mutations in affected individuals (1 19). A comprehensive database of these mutations 
has been established to assist clinicians and researchers in their study of the disease 
(120). Efforts have been made to relate the specific BTK domain mutated to the severity 
of the phenotype in humans but no definitive connections have been drawn. The 
presence of phenotypic variation in XLA, even among affected individuals with identical 
genetic abnormalities, highlights the existence of modifier genes affecting B cell 
development. Mochfier genes, or some differential requirement for the BTK protein 
between species, is the likely cause of the disparity of disease severity between mouse 
and human, as well. Human BTK mutations that are almost identical to mouse xid do not 
result in a milder XLA phenotype than other BTK mutations. Moreover, mice with a 
targeted null mutation of Btk have a phenotype similar to that of xid mice (121, 122), 
reaffirming that absence of BTK function, not the nature of the mutation, results in the 
species specific B-cell defects seen in XLA patients and xid mice. The BTK gene is 
involved in a wide array of complex functions. Studies of the disease variations between 
mouse and human and among individual human XLA patients have contributed to the 
elucidation of the role of BTK in B cell development and signaling and revealed insights 
into other pathways involved in B cell function. These discoveries have been the subject 
of a number of recent reviews (123-126). New techniques of identifying BTK mutations 
in humans have also led to the identification of several other genetic B lineage defects 
(127). 
Alym~hoplasia !~ap.?k14"'~) 
Alymphoplasia (aly) mutant mice are homozygous for an autosomal recessive 
mutation resulting in absence of lymph nodes and Peyer's patches, structural defects in 
the spleen, and impaired antibody and cell-mediated immune responses (1 28- 130). 
Recent studies have shown that in addition to structural defects in secondary immune 
organs, aly mice have intrinsic defects in both B and T cells (13 1, 132). Thus, the 
abnormal immune function seen in these mice appears to be due to both stromal 
insufficiency and an innate defect in lymphocyte function. 
Recently, Nuclear Factor (NF)-K-B-inducing kinase (Nik) was identified as the 
mutated gene responsible for the aly mutation (133). A member of the mitogen activated 
protein kinase family (134), the Nik gene has since been renamed Map kinase kinase 
kinase 14 (Map3k14) (81) to comply with evolving standard nomenclature. The NIK 
protein is a serinelthreonine kinase involved in the induction of NF-K-B through a 
number of different cytokine receptors (134). The mutation in aly mice encodes a defect 
within the carboxyl-terminal interacting domain of NIK, disrupting its ability to associate 
with the adaptor proteins that target its activity, while leaving its kinase region intact 
(133). 
The mechanisms through which NIK functions in cytokine signaling and how the 
functional NIK deficit seen in aly mice could result in their characteristic phenotypic 
defects are unclear. While it is widely accepted that NIK stimulates NF-K-B activity, the 
receptors that the kinase conveys signals through have not been fully clarified (134-137). 
NF-K-B is a transcription factor that is induced by many cytokines and regulates the 
expression of a large number of immune and inflammatory genes (138, 139). In the 
original report of the discovery of the NIK protein, NIK was implicated in NF-K-B 
induction through TNF receptors, CD95 and IL-1 (134). A recent study using mice 
carrying a targeted deletion of the NIK gene contradicts these findings and implicates 
NIK in regulation of signaling through the lymphotoxin-f3 receptor (137). Although the 
NIK deficient mice used in this latter study have a complete absence of NIK protein 
whereas aly mice produce normal levels of a mutated NIK protein, their phenotypes are 
almost identical. 
The human NIK gene was considered an interesting positional and biological 
candidate for frontotemporal dementia with parkinsonism linked to Chromosome 17 
(FTDP-17) (OMIM 600274) (140). However, mutational screening has not revealed 
concomitant mutations of the NIK gene with FTDP-17 (140). Mutations in the gene 
encoding microtubule-associated protein tau (MAPT) have since been found associated 
with some cases of FTDP-17 (141). There are currently no known human diseases 
caused by mutations in the NIK gene. However, X-linked anhidrotic ectodermal 
dysplasia with immune deficiency (EDA-ID) (OMIM 300291) has recently been reported 
to be associated with mutations in the gene IKBKG (142), which encodes a protein (IKK- 
y, NEMO, FP-3) that interacts with the NIK protein (143) and is involved in regulation 
of NF-K-B activation. Mutations in IKBKG cause impairment of NF-K-B signaling which 
results in EDA-ID. In addition, a number of inflammatory diseases including rheumatoid 
arthritis, asthma and multiple sclerosis are associated with enhanced NF-K-B induction. 
Studies of aly mice will continue to contribute to the understanding of the complex 
signaling pathways involved in NF-K-B induction in hematopoietic cells. Clarification of 
these pathways will provide further insight into the inflammatory process, assisting in the 
development of novel therapies for a diverse range of inflammatory diseases. 
Beige ( L ~ S ~ ~ )  
The beige (bg) mutation was first identified as a coat color mutation that resulted 
in large, abnormal granules in all granule containing cells, including granulocytes and 
melanocytes (144, 145). In addition to abnormal hair pigmentation, bg mice have 
defective cytotoxic T cell responses and a deficiency in NK cell function. Beige mice 
display increased susceptibility to infection by a number of pathogens, including 
cytomegalovirus (146) and Mycobacterium avium (147). These mice also exhibit a 
reduced ability to reject transplanted tumors and have a bleeding disorder due to a platelet 
storage pool deficiency (148). Characteristic features of the bg mutation are also found 
in Chediak-Higashi Syndrome (CHS) in humans (145, 149) and in a similar disease 
described in a number of other mammals, including mink, cattle, cats and killer whales 
(150). There are also a number of different alleles of bg resulting from distinct 
spontaneous mutations in the mouse (81). 
Complementation analysis had suggested that the same gene was responsible for 
mouse bg, human CHS and CHS-like disease in other species (151). Two groups 
independently identified the mouse bg gene (152, 153), which encodes a widely 
expressed cytosolic protein implicated in the regulation of lysosomal fission (1 54) and 
has been designated the lysosomal trafficking regulator gene (Lyst). Identification of the 
mouse bg gene led to the discovery of a novel human gene with significant sequence 
homology to the mouse gene (153, 155). Sequencing of the human gene, currently called 
CHSI, revealed the presence of mutations in several CHS patients (153, 155). 
Subsequent studies confirmed that the homologous gene was responsible for the CHS- 
like disease in rats (156) and cows (157). The precise function of the CHSIbeige protein 
is not yet clearly understood. Two recent reviews contain useful background information 
and summaries of the current knowledge in the field (148, 158). 
The disease phenotype seen in bg mice and human CHS patients is remarkably 
similar. However, CHS patients commonly develop a lymphoproliferative disorder 
termed the 'accelerated phase' of the disease, which does not occur in bg mice. It has 
recently been reported that intracellular trafficking of CTLA-4 (CD152) is defective in 
CHS patients (159). CTLA-4 is a negative regulator of T cell activation, and the 
decreased expression of this molecule on T cells of CHS patients may disrupt T cell 
homeostasis resulting in the lymphoproliferative syndrome. CTLA-4 trafficking in bg 
mice is relatively unaffected. Therefore, the absence of the lymphoproliferative disease 
in bg mice may be a function of species-specific variations in intracellular processing of 
the CTLA-4 protein. 
Osteopetrosis !C?floP) 
Mice homozygous for the osteopetrosis (op) mutation are small in size and 
toothless, with a shortened lifespan and reduced fecundity. They have a severe osteoclast 
deficiency and exhibit defects in bone remodeling (160). The op mutation affects the 
development and differentiation of most macrophage subpopulations, resulting in reduced 
numbers of osteoclasts as well as tissue macrophages in op mice (161), functional deficits 
in peritoneal macrophage populations (162, 163) (reviewed in (164)) and phenotypic 
abnormalities in dendritic cells (165). Due to reduction of marrow cavity volume, bone 
marrow hematopoiesis in op mice is severely reduced (162), and compensatory 
extramedulary hematopoiesis is seen in both spleen and liver (166). 
Transplantation of bone marrow or spleen cells from wild type mice does not 
rescue the osteopetrotic phenotype of op mice (167). This observation suggested that the 
op defect was in the stromal microenvironment rather than the hematopoietic stem cells 
themselves, and led to the discovery that the op mutation is a single base change in the 
macrophage colony stimulating factor gene, Csfl (168). This gene encodes macrophage 
colony stimulating factor (CSF-1, also called M-CSF), which is a cytokine involved in 
regulating osteoclastogenesis and macrophage production. CSF-1 also plays a role in 
brain development (169) and in both male and female reproduction (for reviews, see 
(170, 171)). 
Of the many forms of osteopetrosis in humans, none has yet been proven 
associated with mutations in the human CSFl  gene. An autosomal dominant form of 
osteopetrosis showed linkage to the chromosomal region in which human CSFl  is located 
(172), but mapping data did not confirm linkage with the CSFl  gene (173). Nonetheless, 
op mice and other osteopetrotic mutants have been very valuable in studying normal bone 
biology as well as the pathophysiology of bone resorption disease in humans (for review, 
see (174)). Much of the current knowledge of the physiological functions of CSF-1 has 
been discovered through the study of osteopetrotic mice. 
Defective lipopolysaccharide response !Tlr4b"d) 
Bacterial endotoxin is a component of the cell wall of Gram-negative bacteria. 
Also know as lipopolysaccharide (LPS), endotoxin elicits a potent inflammatory response 
in most strains of mice as well as in many other mammalian species. More than 30 years 
ago, it was discovered that C3WHeJ mice exhibited a defective immune response to 
lipopolysaccharide (175-177), providing a model to study the physiology of the 
endotoxin response as well as the genetic control of this response (178). The defective 
allele for the endotoxin response was labeled Lpd, to distinguish from the normal allele, 
LP s" 
Endotoxin exerts its effect on multiple cell types in the immune system (179). 
The normal endotoxin response includes mitogenic stimulation of B cells (180, 181), 
proliferation of a subpopulation of T cells (1 82), macrophage cytotoxicity (1 83) and 
inhibition of the phagocytic capacity of macrophages (184). C3WHeJ mice are defective 
in these normal cellular responses to LPS. They do not produce the high levels of pro- 
inflammatory cytokines that normally characterize the LPS response, and are therefore 
more resistant to the lethal effects of LPS (185). As a result, however, C3WHeJ mice are 
more susceptible to infection by Gram-negative organisms (186, 187). In 1977, it was 
reported that C57BUlOCr mice also exhibit a defective LPS response (188), which was 
mapped to the same locus disrupted in the C3WHeJ strain (189, 190). 
The mutations responsible for defective LPS responses in mice were recently 
found to disrupt the Toll-like receptor-4 (Tlr4) gene (191, 192). Toll-like receptors play a 
key role in the induction of the innate immune response, which is the first line of defense 
against infectious organisms (for review, see (193, 194)). The family of mammalian 
Toll-like receptors have significant homology to Drosophila Toll (195) (for review, see 
(196)). TLR4 is a transmembrane protein that conveys signals which activate NF-KB to 
promote expression of the genes involved in the LPS response (197). TLR4 appears to 
function only in the LPS response pathway, so other immunological functions are normal 
in ~psdmice. Mice with a targeted mutation of the 77r4 gene have a phenotype that very 
closely resembles that of C3H/HeJ mice carrying the Lpsd allele (198). While both 
C3WHeJ and C57BUlOCr mice have mutations in 77r4, differences had been observed 
in levels of interferon (IFN)-y production between the two strains in response to various 
microorganisms (199). This variation has recently been recognized as the result of a 
second mutation in the C57BUlOCr strain, in the ZL-12Rb2 gene (200), which results in 
deficient induction of IFN-y through the IL-12 receptor (201). Thus, C57BUlOCr mice 
are even more resistant to the toxic effects of LPS than C3WHeJ mice. 
In humans, exposure to inhaled endotoxin can cause various degrees of airway 
inflammation and asthma (202). The observation that certain individuals are sensitive to 
environmental endotoxin exposure while others are more resistant prompted the 
examination of the genetic regulation of t h s  response in humans. Screening of a group 
of subjects for both TLR4 mutations and degree of responsiveness to inhaled LPS 
revealed that mutations in the human TLR4 gene were associated with airway 
hyporesponsiveness to LPS challenge (203). Like the C3WHeJ mouse, humans with 
reduced endotoxin responsiveness may be more susceptible to infection by Gram- 
negative organisms. Further examination of the role of TLR4 in LPS signaling may 
disclose new approaches in the treatment of endotoxin mediated diseases. 
Other mutations {microphthalrnia (Mi@). wasted (E~?fla2""). hairless (hr)l 
A number of other spontaneous mouse mutations have immunological 
abnormalities as a component of a broader phenotype. One of these is microphthalmia 
(mi) (204). Mutations at this locus affect pigmentation, secondary bone resorption, eye 
development, hearing and immunological function (reviewed in (205)). The 
immunological changes include reduced numbers and deficient function of mast cells and 
NK cells (206) and osteoclast defects resulting in osteopetrosis (207). The mi gene has 
been identified as a transcription factor in the basic-helix-loop-helix-leucine zipper 
(bHLH-ZIP) family (208,209), now named Mi& whlch regulates transcription through 
binding to specialized motifs found in melanocyte specific promoters. Recent studies 
suggest that the immunological defects may be due both to a defect in the bone marrow 
microenvironment (2 10) and to intrinsic cellular abnormalities (2 1 1 , 2  12). See (2 13, 
214) for reviews of the role of MITF protein in melanocyte signaling and development. 
Mutations in human MZTF have been found associated with Waardenburg syndrome 
(WS) type II (215,216). WS type I ( O m  193500) and type III (OMIM 148820) are 
caused by mutations in the PAX3 gene (217) which has been shown to regulate MZTF 
gene expression (2 1 8). 
Mice homozygous for the wasted (wst) mutation were noted for their neurological 
phenotype. Characterized by development of tremors and ataxia beginning at about 21 
days of age, followed by weight loss, progressive paralysis and lymphoid hypoplasia, wst 
mice die shortly after weaning (219). The immunological abnormalities of wst mice 
include increased sensitivity of hematopoietic cells to the cytotoxic effects of ionizing 
radiation (219,220), defects in secretory Ig responses (221,222), disproportionate T-cell 
subsets with abnormalities in cytokine levels (223) and sensitivity of thymocytes to 
apoptosis (224). The wst mutation is caused by a deletion in Eefla2 gene encoding an 
isoform of eukaryotic translation elongation factor la (EFla) (225). Eefla2 is expressed 
only in brain, heart and skeletal muscle, and plays a role in protein synthesis in 
mammalian cells (226)(for review, see (227)). The neurological phenotype in wst mice is 
presumably related to defects in protein translation in the absence of EFla2 in brain, 
heart and skeletal muscle of these mice. However, questions still remain as to how loss 
of this protein can cause the immunological deficits seen in wst mice, since the protein 
has not been detected in splenic tissue of either mice or rats (225). Although wst was 
originally proposed to be a model of ataxia telangiectasia (AT) (219,228,229), AT is 
now known to be associated with mutations in the human ATM gene (230). The human 
homologue of the wst gene, EEFlA2, has been identified and sequenced (23 I), but there 
is currently no known disease caused by mutations of this gene in humans. 
The most apparent feature of the hairless (hr) mutation is total loss of hair 
beginning at 3 - 4 weeks of age (232-234). In addition to alopecia, hr mice also have age 
related immunological defects and a high incidence of thymic lymphoma (235-237) (for 
review, see (238,239)). There are a number of different hr alleles (81). The wild type 
gene encodes a predicted 1182 amino acid protein, 'HR', containing a zinc finger domain 
with a 4-cysteine motif (240). The hr gene is widely expressed, and it has been 
speculated that the HR protein may act as a transcription factor (240); however, its true 
functions have not yet been resolved. Although thymic defects have been reported in hr 
mice, no evidence of hr protein expression has been detected in the thymus (241). 
Mutations of the human HR gene have been found in individuals with congenital atrechia 
with papules (242-245). This disorder is characterized by complete hair loss and papular 
lesions similar to those seen in mice homozygous for the rhino allele of hairless (hJh); 
however, immunological abnormalities have not been reported in these patients. The 
molecular basis of the hairless mutations and currently known functions of the hr gene in 
both humans and mice have been reviewed recently (246-248). 
Motheaten (Hcph") 
The original motheaten (me) mutation occurred spontaneously on the inbred 
C57BW6J background (249). Homozygous me mice are severely immunodeficient, 
express high levels of serum autoantibodies (250-253) and die at approximately 3 weeks 
of age from inflammatory lesions in the lungs and elsewhere. A second mutation at this 
locus, 'viable motheaten' (me"), was reported in 1984 (250). Homozygous mev mice have 
a similar but less severe phenotype, with a lifespan of approximately 9 weeks. The 
longer lifespan of mevmice in comparison to me mice allowed more extensive study of 
the nature of the mutation. 
In 1993, the motheaten mutations were determined to be in the hematopoietic cell 
phosphatase (Hcph) gene (254,255). The Hcph gene encodes the Src homology region 2 
(SH2) domain-containing protein tyrosine phosphatase- 1 (SHP- 1) (256,257), which 
functions as a negative regulator of signaling through a number of hematopoietic growth 
factor receptors. SHP-1 exerts its negative regulatory role in hematopoietic cell growth, 
dfferentiation and activation by dephosphorylating receptors, such as CD72, receptor- 
associated tyrosine kinases such as ZAP-70 or Jak2, and other signaling molecules 
recruited through adaptor proteins such as Grb-2. (For a thorough review of SHP-1 
signaling see (258)). SHP-1 has also recently been found to play a critical role in the 
induction of apoptosis and cell cycle arrest in response to y-irradiation (259). The 
phenotypic differences between the two allelic mutations at the me locus are due to a 
variation in expression levels of the SHP-1 protein. The me mutation results in the total 
absence of SHP-1 protein due to creation of a premature termination codon, while the mev 
mutation (HcphmV) results in a significant reduction in SHP-1 activity due to the 
generation of several alternative splicing sites. 
Although the motheaten mutations are not a model for any known human disease, 
they provide a valuable resource for the study of the role of a specific protein tyrosine 
phosphatase (PTP) in the development and regulation of the immune and hematopoietic 
systems. Studies of motheaten mice have provided insight not just into the function of 
the SHP-1 phosphatase but into the general function of phosphatases and their integral 
role in regulating an enonnous variety of cell signaling cascades and cell functions (258). 
The human homologue of the mouse Hcph gene is called PTPN6 (260). No known 
heritable mutations exist in human PTPN6. If germ-line mutations in this gene do occur 
in humans, they may well result in embryonic lethality. Recently, however, aberrant 
SHP-1 expression has been associated with a variety of human cancers. An errant splice 
product of PTPN6 has been found in human myeloid leukemia cells (261). This post- 
transcriptional processing error is thought to result in a functional haplo-insufficiency of 
SHP-1 protein, possibly contributing to leukemogenesis (261). SHP-1 expression is 
absent or significantly reduced in many human T-cell lymphomas as a result of a 
transcriptional block caused by methylation of the SHP-1 promoter (262). The absence 
of SHP-1 protein is associated with constitutive activation of the interleukin 2-receptor 
(LL-2R) -associated JakISTAT pathway and may contribute to the malignant 
transformation human T cells (262). Defective expression of SHP-1 has also been 
implicated in the pathogenesis of polycythemia Vera (263), and up-regulation of SHP-1 
expression has been found associated with human breast cancers (264). 
Conclusion 
Determination of the molecular bases of mouse immunological mutations has 
increased the understanding of the mechanisms of disease and aided in elucidating the 
roles of these genes in the intact immune system. Certain of these immunological 
mutations serve as homologues for human immunodeficiency and autoimmune diseases 
(70, 81,265). Although the pathological changes related to these mutations may be 
affected by physiological differences between mouse and man, the mouse models provide 
an invaluable resource for biomedical researchers. Continued studies of new 
immunological mutations at The Jackson Laboratory and elsewhere will likely lead to 
further insights into the fundamental aspects of immune defense and expand the 
knowledge of the immune system. 
Chapter 2 
SHP-1 PROTEIN TYROSINE PHOSPHATASE AND THE "MOTHEATEN" 
MOUSE 
Tyrosyl phosphorylation is a key regulatory mechanism involved in development 
and function of the immune system. The intricate dance between tyrosine kinases and 
phosphatases is crucial for maintaining balance in hematopoietic signaling. One misstep 
can have severe consequences, resulting in autoimmunity, immune deficiency, or cancer. 
As a result of the development of gene targeting techniques, there are now many mouse 
models lacking specific components involved in regulation of immune function. 
However, one of the first models for a specific tyrosine phosphatase deficiency was 
found in mice with one of two spontaneous allelic mutations at the motheaten locus, 
introduced in Chapter 1 of this manuscript. 
As discussed in Chapter 1, mice carrying mutations at the motheaten locus are 
deficient in SHP-1 (249,250,254). SHP-1 is a cytosolic protein tyrosine phosphatase 
(FTP) that plays a crucial role in regulating proliferation, differentiation, and other 
signaling processes in cells of the immune and hematopoietic systems. (For a review of 
FTP's in signal transduction, see (266)). As a result of SHP-1 deficiency, mice 
homozygous for the me or mev mutations have multiple hematological and 
immunological defects that are discussed in detail elsewhere. In addition to being 
valuable tools for the elucidation of SHP-1 function, studies using me and mev mice have 
provided many insights into a wide range of signaling pathways and mechanisms 
essential to maintenance of immune homeostasis (267). 
SHP-1 functions primarily in the negative regulation of hematopoietic signaling 
events induced by cytokines, growth factors and antigens (for review, see (258)). The 68 
kD SHP-1 protein, (previously known as PTP-lC, HCP, SHP, SHPTPl and PTPN6), 
contains two N-terminal Src-homology 2 (SH2) domains, a phosphatase catalytic region, 
and a C-terminal region compatible with tyrosine phosphorylation (257,267) (Figure 
2.1). The SH2 domains mediate the recruitment of the SHP-1 protein to phosphorylated 
tyrosine residues within immunoreceptor tyrosine-based inhibitory motifs (ITIM's) in the 
cytoplasmic regions of inhibitory receptors and co-receptors (see review (268)). 
Structural rearrangement of the SHP-1 protein as a result of SH2 domain binding 
activates the phosphatase catalytic domain (269), which dephosphorylates the intended 
substrate, resulting in signal inhibition. 
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Figure 2.1. Structure of SHP-1, showing the locations of the me and mev mutations. 
SHP-1 has been shown to interact with a variety of both cytoplasmic and 
membrane bound molecules in the regulation of B-cell signaling, including Lyn kinase, 
CD22 (270), paired immunoglobulin-like receptor B (PIR-B) (271) and CD72 (272) 
(Figure 2.2). The SHP-1 phosphatase is also involved in regulation of T cell receptor 
(TCR) signaling function (273) (Figure 2.3). SHP-1 associates with CD5, which is a 
transmembrane protein expressed on all T cells, and the B-la subset of B cells (274). 
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Figure 2.2. Functions of SHP-1 in regulating signals through the B-cell receptor (BCR). 
After BCR cross linking, the Src-family protein tyrosine kinase (PTK) Lyn has the 
principal role in phosphorylation of tyrosine residues in both the immunoreceptor 
tyrosine-based activation motifs (ITAMs) of Ig-do, as well as in the ITIMs of inhibitory 
co-receptors (such as CD22, PIR/B, CD72 and FcyRIIB). Phosphorylation of ITIMs by 
Lyn results in recruitment of SHP-1 through its SH2 domains. From its position at the 
cell membrane, SHP-1 dephosphorylates activated PTK's and, by extension, PTK 
substrates, resulting in inhibition of BCR mediated signals. (Figure based on (258)). 
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Figure 2.3. Functions of SHP-1 in regulating signals through the T-cell receptor (TCR). 
TCR engagement induces the transphosphorylation of the Syk-family PTK ZAP-70 by 
the Src-family PTK Lck, which is associated with the CD4JCD8 co-receptor. The 
consequent phosphorylation of ITIMs within inhibitory receptors such as KIR, Ly-49A 
and CD5 results in recruitment of SHP-1 through its SH2 domains. SHP-1 can directly 
associate with and dephosphorylate receptors or activated PTKs, or indirectly 
dephosphorylate other signaling effectors such as SLP-76, through association with 
adaptor proteins such as Grb2. (Figure based on (258)). 
B-la B cells are often associated with autoimmunity in humans (reviewed in (275)), and 
constitute a large percentage of total B cells in mev/mev mice. Chapter 3 describes studies 
using mice homozygous for both the mev mutation, and a targeted deletion of the CD5 
gene. These mice were developed to investigate the function of CD5-mediated signaling 
in development of autoimmunity in the absence of SHP-1, as well as to provide insight 
into the role of SHP-1 in regulating signals through the CD5 receptor. 
Cells of the myeloid lineage are also dependent on SHP- 1 to regulate signals 
through a multiplicity of receptors. In particular, macrophages from motheaten mice are 
hyper-responsive to signals through receptors for granulocyte-macrophage colony- 
stimulating factor (GM-CSF) (276) and macrophage colony stimulating factor (M-CSF or 
CSF-1) (277), which direct proliferation and survival of cells of the granulocyte- 
macrophage lineage and their progenitors. Heightened proliferation and accumulation of 
myeloid-lineage cells is a characteristic of the motheaten mouse. Chapter 4 describes the 
generation of mice transgenic for macrophage specific expression of a dominant negative 
form of the SHP-1 protein, to investigate the cell autonomous effects of absence of 
functional SHP-1 in macrophages and the effects of dysregulated macrophages on other 
cell populations. 
With the known role of SHP-1 as a negative regulator of cell signaling, it is 
logical to postulate that loss of function of this regulatory protein could contribute to 
malignant transformation, or that SHP-1 can act as a tumor suppressor gene. The 
association of SHP-1 mutations with human cancers is discussed in the section on the 
"motheaten" mouse in Chapter 1 (261,262). Studies are ongoing in our lab to identify 
neoplasms arising in aged +/me and +/mev mice caused by loss of SHP-1 heterozygosity, 
in order to substantiate the putative role of SHP-1 as a tumor suppressor gene (254). 
Chapter 5 describes an osteogenic cell line derived from a spontaneous osteosarcoma that 
arose in a 25-month old C57BU6J +/mev mouse. Preliminary studes of this malignant 
neoplasm revealed that it was not caused by loss of expression of the SHP-1 protein. 
However, the cell line by itself, or when used in transplantation experiments, has value as 
a model for studying human osteosarcomas. 
Several other molecules exist which share some structural homology with SHP-1, 
includng SHP-2 (278) and an SH2 containing inositol polyphosphate 5'-phosphatase, 
SHIP (279), both of which contain SH2 domains and may serve purposes similar to SHP- 
1 in some incidences. However, it is evident by the severity of disease caused by SHP-1 
deficiency that there are few, if any, precisely redundant molecules that may serve as a 
substitute for SHP-1 in living systems. The known biological roles of SHP-1 are 
multitudinous, yet many of its functions still remain a mystery. Further investigation into 
the functions of this phosphatase may provide clues to expand the knowledge of a great 
many signaling pathways involved in normal immunological function. 
Chapter 3 
ABSENCE OF CD5 DRAMATICALLY REDUCES PROGRESSION OF 
PULMONARY INFLAMMATORY LESIONS IN SHP-1 PROTEIN-TYROSINE 
PHOSPHATASE-DEFICIENT "VIABLE MOTHEATEN" MICE 
Abstract 
Mice homozygous for the viable motheaten (Hcphm+) mutation are deficient in 
SHP-1 protein-tyrosine phosphatase, resulting in severe systemic autoimmunity and 
immune dysfunction. A high percentage of B-cells in viable motheaten mice express the 
cell surface glycoprotein CD5, in contrast to wild type mice that express CD5 on only a 
small percentage of B-cells. CD5' B-cells have been associated with autoantibody 
production. To determine the role of CD5 in the development of the inflammatory 
disease in mev/mev mice, we created a stock of CD5-'-mev/mev mice. The longevity of 
CD54mev/mev mice was increased 69% in comparison to mev/mev mice on a similar 
B6;129 background. The increased lifespan was associated with a marked reduction in 
pulmonary inflammation. Flow cytometry analysis of spleen cells from CD5'- mev/mev 
mice at 9 - 12 wks of age revealed significant decreases in percentages of IgMlB220 
double positive B-cells, Mac-11Gr-1 double positivecells and CD4'T-cells compared 
with mev/mev mice. CD5-'- mev/mev mice also had significantly lower serum IgM levels in 
comparison to mev/mev mice. Study of CD5'- mev/mev mice may provide further insight 
' Modified from: Joliat W, Lang PA, Lyons BL, Lynes MA, Yi T, Sundberg JP, Shultz LD. Absence of 
CD5 dramatically reduces progression of pulmonary inflammatory lesions in SHP-1 protein-tyrosine 
phosphatase-deficient viable motheaten mice. J. Autoimmun. In press. 
into the role of CD5 in cell signaling and may help explain the observed association of 
CD5' B-cells with autoimmune disease. 
Introduction 
Mice homozygous for either of the two recessive allelic mutations in the 
hematopoietic cell phosphatase (Hcph) gene on Chromosome 6 are severely 
immunodeficient, express high levels of serum autoantibodies (250-253) and die at an 
early age from inflammatory lesions in the lungs and elsewhere. The Hcph gene encodes 
the Src homology region 2 (SH2) domain-containing protein tyrosine phosphatase-1 
(SHP-1) (256, 257), which is a negative regulator of signaling through a number of 
hematopoietic growth factor receptors (258, 276, 280). The two mutant alleles of the 
Hcph gene that arose spontaneously in C57BU6J mice are 'motheaten', (Hcphme, 
abbreviated me) and viable motheaten (Hcphm+, abbreviated mev). The me mutation is 
due to a cytosine deletion that results in the total absence of the SHP- 1 protein due to 
creation of a termination codon. Death of me/me mice occurs at approximately 3 wks of 
age. The mev mutation is a thymine to adenine transversion that results in creation of 
alternative splicing sites and an 80% to 90% reduction in SHP-1 activity compared with 
wild type mice. Homozygous mev/mev mice live to approximately 9 wks of age and are 
thus the more commonly used model to study the consequences of deficiency in SHP- 1 
protein tyrosine phosphatase (254). 
In addition to autoimmunity and severe pulmonary disease, meV/mev mice have 
many additional cellular abnormalities, including an increase in myelopoiesis (250, 281) 
and multiple defects in lymphocyte development and function (282-285). A large 
percentage of B-cells present in mev/mev mice express CD5 (286), which is normally 
found only on T-cells and a small percentage of B-cells in wild type mice. 
CD5 (Ly-1) is a monomeric 67-kD membrane glycoprotein expressed on all 
mature T-cells and on a subset of B-cells, termed B-la cells. Classified structurally as a 
member of the scavenger receptor family (287), CD5 consists of a cysteine rich 
extracellular region and a cytoplasmic domain containing motifs compatible with 
phosphorylation by tyrosine and serinelthreonine lunases (Figure 3.1). CD5 is part of the 
TCR complex. It is expressed at low levels on immature, CD4TD8' thymocytes and is 
upregulated in differentiated T-cells (288). Tyrosine residues within the CD5 
cytoplasmic region are phosphorylated upon TCR stimulation (289). Recently, it was 
reported that CD5 functions as a negative regulator of signal transduction through the 
TCR, affecting thymocyte differentiation as well as mediating TCR signaling in mature 
cells (290-292). CD5 has been found to be constitutively associated with SHP-1 in Jurkat 
T-cells and normal phytohemagglutinin-expanded T-lymphoblasts (274), indicating that 
the negative regulatory role of CD5 in T-cells may be medated through SHP-1. 
Figure 3.1. Structure of CD5. The extracellular region contains three scavenger receptor 
cysteine-rich domains, while the cytoplasmic region contains motifs compatible with 
SerIThr or Tyr phosphorylation. 
CD5 is associated with the B-cell receptor (BCR) on B-la cells (293). In wild 
type adult mice, cells expressing CD5 constitute a significant percentage of the B-cell 
population in the peritoneal and pleural cavities, while they are scarcely found in the 
splenic B-cell pool (294). Although the function of CD5 on B-cells is poorly understood, 
B-la cells, that express CD5, are associated with production of natural autoantibodies 
(295), specifically of the IgM isotype (296). An increase in the number of B-cells 
expressing CD5 is often associated with increased production of autoantibodies 
(reviewed in (275)). In me/me and mev/mev mice, virtually all of the B-lymphocytes, 
including the splenic populations, express CD5 (297). We theorized that CD5 deletion in 
mev/mev mice would result in reduction of sytemic autoimmunity in these mice. 
CD5 deletion in otherwise wild type mice does not interfere with the ability of 
these mice to mount an efficient immune response (294). T-cells from C D ~ - /  mice are 
hyperreactive in response to TCR mediated signals in vitro (290), but this increased 
reactivity has no apparent detrimental effect on T-cell function in vivo. Thus, mice 
lacking CD5 are healthy and have normal distribution of lymphoid and myeloid cells. To 
explore the effect that CD5 expression has on the autoantibody production and 
inflammatory disease of viable motheaten mice, we crossed 1 2 9 - ~ d 5 ' ~ ' ~ ~ "  (CD5.') mice 
with C57BLl6J-mevmice to create a stock of mice homozygous for the CD5 deletion and 
segregating for the viable motheaten mutation. Comparison of the phenotypes of mev/mev 
mice with or without CD5 revealed a marked role of this molecule in the development of 
immunopathologic changes in mev/mev mice. 
Materials and Methods 
Mce 
All mice were raised at the Jackson Laboratory (Bar Harbor, ME). 1 29-Cd5tm'Cg" 
(CD5-I-) mice (294) were first crossed with heterozygous C57BU6J-+/mev mice. 
Offspring were heterozygous for CD5-I- and were typed for the presence of the mev 
mutation. Mice that were heterozygous for both the mev mutation and CD~'- were 
intercrossed. Homozygous CD5-I- mice from these matings that were heterozygous for 
the mev mutation were then intercrossed to create a B6; 129-CD54 mev stock in which the 
CD5 null allele was fixed to homozygosity and the mice were segregating for the mev 
mutation. Concurrently, 129P3lJ wild type mice were bred with C57BU6-+/mev mice in 
order to produce mev/mev and +/? control mice on a matched segregating background that 
expressed normal CD5 levels. Mice were typed for the CD5 null allele by PCR, using 
primers for the inserted neomycin resistance gene (neol3: 5'- 
CPGGGTGGAGAGGCTAIITC-3', neo14: 5'-AGGTGAGATGACAGGAGATC-3'). 
Determination of the genotype at the Hcph locus (mev/mev, +/mev or +/+) was also 
conducted by PCR, using primers flanking the viable motheaten mutation (mev-F: 5'- 
CGTGTCATCGTCATGACT-3', mev-R: 5'-AGGAAGPGGGGCTTTGCCGT-3'). 
Before electrophoresis, the amplification products were digested with RsaI to distinguish 
among +/+, +/mev and mev/mev mice (298). Mice were housed in conventional pathogen- 
free animal facilities (299). 
Histopathology 
Groups of mice from 4 - 18 wks of age were euthanized by CO, asphyxiation. 
Tissues were fixed in Fekete's acid alcohol formalin, embedded in paraffin, and sectioned 
at 6 pm. Slides were stained with Mayer's hematoxylin and eosin (H&E) and Periodic 
Acid Schiff (PAS) for histological examination. Immunohistochemistry was carried out 
on lung and kidney sections using biotinylated rabbit anti-mouse Ig (DAKO, Carpinteria, 
CA) for identification of immune complexes. Non-specific staining was blocked on 
deparaffinized sections with peroxidase blocking reagent (DAKO). Tissues were then 
incubated in primary antibody for 1 h at room temperature in a humidified chamber. 
After three 5 min washes in PBS, tissues were incubated with avidinlhorseradish- 
peroxidase conjugate for 45 min, followed by an additional trio of 5 min washes in PBS. 
Tissues were then incubated in diaminobenzidine (DAB) for 5 min at room temperature 
and washed in tap water for 5 to 15 rnin. Tissues were counterstained with hematoxylin, 
dehydrated in graded ethanol, cleared in xylene, and coverslipped with Permount (Fisher 
Scientific, Pittsburgh, PA). 
Flow cytometric analysis 
Monoclonal antibodies, conjugated with phycoerythrin, FITC or biotin, were used 
for characterization of spleen cells from 9 - 12 wk-old and 15 - 18 wk-old mice. 
Streptavidin-Red 6-70 was used as a secondary fluorophore for biotinylated antibodies. 
The following antibodies were obtained from PharMingen, Inc. (San Diego, CA): anti- 
CD4, clone RM4-5; anti-pan granulocyte (Gr-1), clone RB6-8C5 (300); anti-Mac-1, 
clone MI170 (301); anti-CD23, clone B3B4 (302,303); anti-CD43, clone S7 (304-306); 
and anti-CD19, clone 1D3 (307-309). Additional antibodies, as follows, were purified 
from hybridoma cell lines as ascites; anti-CD3, clone 145-2C11 (310); anti-CD8, clone 
53-6.72 (31 1,312); anti-IgM, clone R6-60.2; anti-B220, clone RA3-6B2 (313); anti-pan 
macrophage, clone F4180; anti-MHC class I, clone MI142 (314); anti-MHC class Il, clone 
M511 14 (315); anti-pan erythrocyte, clone Terl19 (316); and anti-CD5, clone 53-7.3 
(31 1,312). Single cell suspensions were prepared from individual spleens by extrusion 
of cells through Nytex 110 mesh bags (TETKO Inc., Elmsford, NY) into cold HBSS 
containing 5% FBS and 0.1% sodium azide. Erythrocytes were lysed in buffered 
ammonium chloride, and leukocyte populations were phenotyped as previously described 
(297) using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). B-1 B- 
cells were identified by labeling cells with antibodies against IgM, CD19, and CD43. 
Cells that were I ~ M ~ ~ ~ ,  CD19+, CD43+ were considered B-1 B-cells (3 17, 31 8). 
Ig levels 
Levels of IgM, IgGl, and IgG3 in serum from 9 - 12 wk-old individual mice were 
assayed by ELISA as previously described (297). Plates were coated with goat anti- 
mouse isotype specific antibody (Southern Biotechnology Associates, Birmingham, AL). 
Alkaline phosphatase labeled goat anti-mouse K-chain (Southern Biotech) was used as 
the detection antibody. Isotype specific standards (PharMingen) were run with each 
assay. Plates were developed with p-nitrophenyl phosphate (Sigma Chemical Co., St. 
Louis, MO) and read with the EL 3 12e Bio-Kinetics Reader (Bio-Tek Instruments, 
Winooski, VT). Ig levels were determined from the standard curves. 
Autoantibody determinations by ELISA 
Circulating autoantibodies against histone proteins were determined using a 
modification of a protocol described by Amoura et al. (319). In brief, individual wells of 
96 well microtiter plates were first coated with 100 p1 of 2 pg/pl calf thymus histone 
protein (Type IIS, Sigma) in PBS for 1 h at 37°C. The wells were then washed in an 
automated microplate washer with PBS containing 0.25% Tween 20 (PBSIT~O), and then 
blocked with 200 p1 PBS containing 1% BSA for 1 h at 37°C. The wells were washed, 
and 100 p1 of each serum dilution was added to the appropriate wells. After incubation 
for one additional hour at 37"C, the wells were washed three times, and then 100 pl of a 
previously titered goat anti-mouse IgG (H+L)-alkaline phosphatase conjugate was added 
to each well. Following incubation at 37°C for 1 h, the plates were washed, and then 100 
p1 substrate (p-nitrophenyl phosphate, Sigma) dissolved at 1 mg/ml in diethanolamine 
substrate buffer was added to each well. The rate of substrate conversion to colored 
product at 37°C was monitored at 405 nm and recorded as mODImin. Autoantibodies 
against double stranded DNA were detected according to a modification of a protocol 
described by Zouali et al. (320). In brief, microtiter wells were coated with calf thymus 
DNA at 10 pg/ml in TBS (10 mM Tris base, 150 mM NaCI, pH 7.4) for 2 h at room 
temperature. Following this incubation, the plates were washed with PBS/T20 in an 
automated microplate washer, and then processed as described above. 
Hematology 
Blood was collected from the retro-orbital sinus using heparinized capillary tubes. 
Leukocytes and erythrocytes were counted using a model ZBI Coulter counter (maleah, 
FL). Mean corpuscular volumes (MCVs) were calculated from the packed red cell 
volumes and total RBC counts as previously described (250). Blood smears were stained 
with Wright-Giemsa (Sigma) for examination of cells for morphological abnormalities. 
Reticulocytes were counted using the ADVIA 120 Hematology system (Bayer Corp, 
Tarrytown, NY). Confirmation of reticulocyte percentages was conducted manually 
following staining with New Methylene Blue (NMB) stain (Mallinckrodt Baker Inc., 
Phillipsburg, NJ). Equal amounts of blood and stain were incubated together in a 
capillary tube for 15 min and smears were prepared. The smears were then air-dried and 
coverslipped with Permount (Fisher). 
Spleen cell lysates and immunoblotting 
Spleens were dissected from mutant and control mice at 5 - 8 wks of age and at 
12 - 15 wks of age. Single cell suspensions were prepared after lysis of red blood cells 
following established procedures (321). For irnrnunoblotting, the spleen cells were lysed 
at 4°C for 30 min in cold lysis buffer (20 mM Tris, pH 7.4; 1 mM EDTA; 10% glycerol; 
1% Triton X-100; 100 mM NaCl; 1 pg of leupeptin per ml; 1 pg of aprotinin per ml; 1 
mM bezarnidine and 5 mM of iodoacetic acid). Cell lysates were clarified by 
centrifuging for 10 min at 10,000g at 4" C. Protein levels were measures using the DC 
Protein Assay (Bio-Rad, Hercules, CA). 20 pg of each sample was resolved in a 12.5% 
SDS-PAGE gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, 
Dassel, Germany). The membranes were probed, as described previously (322), with 
monoclonal antibody against phosphotyrosine (4G10, Upstate Biotechnology Inc., Lake 
Placid, NY). Specific antibody signals were detected using an enhanced 
chemiluminescence kit (ECL, Amersham Pharmacia Biotech, Uppsala, Sweden). 
Bone marrow macrophage cultures 
Bone marrow plugs from femurs and tibias were harvested by extrusion with cold 
HBSS. Marrow plugs were disrupted by passage through a 25g needle. The resulting 
single cell suspensions were washed 2x in sterile HBSS (Sigma), counted with a model 
ZBI Coulter counter and resuspended in complete media (RPMI-1640 (Sigma) containing 
2 mM L-glutamine, 10% FCS, 100 Ulml penicillin and 100 pglml streptomycin). A total 
volume of 5 ml medium containing lo6 cellslml was added to 25 cm2 tissue culture flasks 
with either 500 or 1000 unitslml of recombinant human (rHu) CSF-1 (Cetus) or 
recombinant murine (rMu) GM-CSF (R&D Systems, Minneapolis, MN). Cultures were 
incubated at 37°C in 5% CO, for 24 h to allow adherent cells to attach to the flask. The 
non-adherent cells were transferred to duplicate flasks and cultured for 7 days with 
periodic changes of media, maintaining the appropriate growth factor concentrations. To 
recover adherent cells from flasks, medium containing any non-adherent cells was 
removed and transferred to 50 ml tubes. The remaining adherent cells were washed 2x 
with 10 ml warm HBSS, then incubated for 10 min with 10 ml2mM EDTAIPBS at 37OC. 
Cultures were vigorously shaken to detach all adherent cells. The adherent cells were 
then combined with the non-adherent cells in 50 ml tubes, washed 2x in HBSS and used 
for FACS analysis as previously described. Preliminary FACS analysis of adherent and 
non-adherent cells separately showed that they had similar staining profiles. In 
subsequent FACS analyses, adherent and non-adherent were combined to increase the 
numbers of cells available for analysis. 
Statistics 
All measures of variance are presented as SEM. Student's t tests were performed 
to determine significance of difference of means. Significance was assumed for p values 
< 0.05. 
Results 
Longevity 
Thirty five B6; 129-CD5" mev/mev mice and an equal number of B6; 129-mev/mev 
mice were monitored daily from three weeks of age (Figure 3.2). There was no 
significant effect of gender on survival of these mice. The mean lifespan of B6;129- 
CD5-I- mev/mev mice (162 +I- 10 d) was significantly increased in comparison to B6;129- 
mev/mev mice, which had a mean lifespan of 89 +I- 8 d (p<0.0001). Our previous studies 
revealed that C57BL6-mev/mev mice had a mean lifespan of 61 +/- 2.4 d (250), indicating 
an effect of strain background on lifespan of these mice. All subsequent data compares 
mev/mev mice, CDFL mev/mevmice and wild type +/+ controls on the B6;129 segregating 
background. Although lifespan data has not been gathered on wild type B6;129 mice, the 
average lifespan of C57BU6J mice is 800 days for males and 750 days for females (323). 
Figure 3.2. Cumulative percent survival of B6; 129-mev/mev and B6; 129-CD5-I- mev/mev 
mice as a function of age. Thirty-five male or female mice from each genotype were 
monitored from 3 wks of age. 
Immunopathology 
In order to determine the effect of the CD5 null allele on the onset and progression 
of the characteristic pathologic lesions of mev/mev mice, total necropsies were performed 
on mutant (CD54 mev/mev and mev/mev) and control (CD5+ +I? and +I?) mice. All tissues 
were examined histologically with a pathologist (J.P.S.) (324). Several striking 
differences were noted in B6;129-CD5+ mev/mev mice when compared to B6;129-mev/mev 
mice. 
Development of pulmonary lesions was significantly delayed in CD5-L mev/mev 
mice in comparison to mev/mev mice. At 9 wks of age, this difference was evident grossly 
at the time of necropsy. Lungs of mev/mev mice were mottled tan in color and firm, while 
lungs of CDSJ- mev/mev mice resembled the lungs of wild type mice and were compliant 
and evenly light pink in color. Histologically, the mev/mev mice developed earlier 
acidophilic macrophage pneumonia (325,326), which progressed in severity more 
rapidly than in CDSL mev/mev . Moderate disease was evident by 4 wks of age in mev/mev 
mice and pneumonia was severe by 9 wks. Pulmonary lesions were minimal or absent in 
CDYL mev/mev mice at 4 wks of age, and by 9 wks of age, only mild peribronchiolitis or 
pneumonitis was observed (Figure 3.3). By 21 wks of age, most CD5-I- mev/mev mice 
developed mild to moderate acidophilic macrophage pneumonia, while one CD5'- 
mev/mev mouse necropsied at 43 wks of age had only mild pulmonary disease (data not 
shown). 
Spleens in CD5-/ mev/mev mice were markedly enlarged. Spleen weight expressed 
as a ratio of spleen to body weight (S:BW) was increased 42% in CDYL mev/mev mice in 
comparison to mev/mev mice (p<0.05) at 9 wks of age. The S:BW of mev/mev mice at 9 
wks of age was increased almost 7 fold over a control group of +/+ and +/? mice 
combined (data not shown). The S:BW of both CD5" mev/mev mice and mev/mev mice 
increased with age from 5 - 18 wks, while in +/? and CD5" +/? mice, this ratio did not 
change considerably with age. The spleens in CDFL me'/mev mice at 9 wks of age had 
poorly defined follicles and contained numerous multinucleated giant cells with abundant 
cytoplasm. While the splenic follicles of mev/mev mice were poorly delineated, the 
spleens lacked the extensive granulomatous lesions, consisting of multinucleated giant 
cells, found in CD5-I- mev/mev mice (Figure 3.4). With increasing age, multinucleated 
giant cells in CD5+ mev/mev mouse spleens became even more abundant, while the 
relative number of these cells in spleens of mev/mev mice increased only slightly. 
The livers in CD5'- mev/mev mice showed marked extramedullary myelo- and 
erythropoiesis at 9 wks of age. In contrast, the livers in mev/mev mice exhibited only mild 
extramedullary hematopoiesis (EMH), mostly myeloid in nature (Figure 3.5). By 16 wks 
of age, EMH in livers of CD5% mev/mev mice had increased considerably, while EMH in 
livers of mev/mev mice remained mild to moderate (data not shown). 
CD5'- mev/mev mice did not develop hyperplasia of the non-glandular stomach, a 
feature commonly seen in mev/mev mice at 9 wks of age (Figure 3.6 A). Inflammation of 
the glandular stomach was observed in both CD5" mev/mev mice and mev/mev mice. Renal 
glomeruli of CD5" mev/mev mice were enlarged and increased in cellularity at 9 wks of 
age, suggesting a mild membranoproliferative glomerulonephritis. The mev/mev mice 
exhibited glomerulonephritis, but the condition was less severe (Figure 3.6 B). Immune 
complexes were detected in the glomeruli of both CD5'- mev/mev and mev/mev kidneys by 
PAS staining and by immunohistochemistry using anti-mouse Ig (data not shown). 
Blood urea nitrogen (BUN) levels were not significantly elevated in either CDSJ- mev/mev 
or mev/mev mice ranging from 6 to 12 wks of age (data not shown). 
Figure 3.3. Photomicrographs of lung of CD~-I- mevlmev mice. Lung shows severe 
eosinophilic macrophage pneumonia in mevlmev mice, in contrast to minor peribronchiolar 
aggregation of lymphocytes in CD5-I- mevlmev mice and normal appearance in +/mev control 
mice. Tissue sections are from 62-64 day old B6; 129 mice. All tissues were fixed in 
Fekete's acid alcohol formalin and stained with hematoxylin and eosin. 
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Figure 3.4. Photomicrographs of spleen of CD5-I- mev/mev mice. Spleens of mev/mev and 
~ D 5 - l -  mevlmev mice have poorly defined lymphoid follicles that are markedly depleted of 
lymphoid cells. Spleens of CD5-I- mevlmev mice contain many multinucleated giant cells 
(arrows) that are not present in mevlmev spleens. In +/mev mice, spleens reveal well-developed 
follicles. Tissue sections are from 62-64 day old B6;129 mice. All tissues were fixed in 
Fekete's acid alcohol formalin and stained with hematoxylin and eosin. 
Figure 3.5. Photomicrographs of liver of CD5-'- mevlmev mice. Livers of mevlmev mice 
exhibit mild extrarnedullary hematopoiesis, mostly myeloid in nature. In contrast, high 
levels of extramedullary myelo- and erythropoiesis are evident in livers of CD5'- meVhev 
mice. The +/mev livers appear normal. Tissue sections are from 62-64 day old B6;129 
mice. All tissues were fixed in Fekete's acid alcohol forrnalin and stained with hematoxylin 
and eosin. 
Figure 3.6. Photomicrographs of kidney and stomach of C D ~ "  mevlmev mice. A) Renal 
glomeruli of CD5-L mevlmev mice are enlarged and increased in cellularity, suggesting of a 
mild membranoproliferative glomerulonephritis. The mevlmev mice show less severe 
glomerulonephritis. B) Hyperplasia of the non-glandular stomach commonly seen in mevlmev 
mice is not present in CD~-I -  mevlmev mice. Tissue sections are from 62-64 day old B6; 129 
mice. All tissues were fixed in Fekete's acid alcohol formalin and stained with hematoxylin 
and eosin. 
Flow cytometry analyses of cell ~opulations 
The observed splenomegaly in CD5& mev/mev and mev/mev mice was accompanied 
by a significant increase in total numbers of nucleated cells in the spleen in comparison to 
CDSd +I? and +I? mice, respectively (pd.05). Average numbers of nucleated 
splenocytes in CDSJ- mev/mev were increased in comparison to mev/mev mice, but the data 
were not statistically significant. An elevation in the number of splenic myeloid cells 
contributes to the splenomegaly observed in mev/mev mice (250). While an increase in 
ratio of spleen weight to body weight (S:Bwt) was observed in CD5-I. mev/mev mice in 
comparison to mev/mev mice, the reduction in severity of acidophilic macrophage 
pneumonia observed in CD5-I- mev/mev mice suggested a general decrease in myeloid 
cells numbers. To determine the proportions of cell populations present in the spleens of 
CD5& mev/mev mice, flow cytometric analysis was performed. 
Percentages of splenic Mac-1' Gr-1' monomyeloid cells were significantly 
reduced in CD5-/ mev/mev mice compared to mev/mev mice, as were percentages of IgM' 
B220' B-cells and CD3' CD4'T-cells (Table 3.1). However, CD5" mev/mev mice had a 
significant increase in percentages of splenic Terl19' erythrocyte precursor cells 
compared to mev/mev mice, suggesting that the augmented splenomegaly in CDSJ- 
mev/mev mice is a result of an increase in erythropoiesis. 
Table 3.1. Flow cytometry analyses of spleen cells from 9 - 12 wk-old B6,129-CD5" 
mev/mev mice. 
- 
B6;129 B6;129 B6;129 B6; 129 Cell Population 
mev/mev CD5-I- mev/mev +/? CD5'- +/? 
B- 1 cellst (as % of 
total B-cells) 
Ter 1 19' 12.6 _+ 2.9 56.2 f 7.8* 2.2 f 1.1 2.2 f 0.8 
- -- - -- - 
Data are expressed as a mean percent f SEM {n = 6 for B6;129-CD5& mev/mev; n = 5 
for B6;129-mev/mev; n = 4 for ~6;129-CD~"' +/? and B6;129-+/? ) {t B-1 cells were 
identified as I~M'@", CD19', CD43') { *  indicates significant (p < 0.05) difference in 
spleen cell populations between CD5'- mev/mev and mev/mev mice) 
Mean # of 
nucleated spleen 3.4 f 0.6 4.4 f 0.7 1.7 f 0.3 1.1 f 0.1 
cells x lo8 
To determine whether CD5 is necessary for development of B-1 cells, percentages 
of these cells were determined using antibodes against IgM, CD43, and CD19. 
Percentages of IgM' B220' B-cells that had a B-1 phenotype did not vary significantly 
between C D 9  mev/mev mice and mev/mev mice (Figure 3.7), indicating that CD5 
expression is not required for development of the B-1 cell population. 
Figure 3.7. Flow cytometry analysis of B-1 B cells in spleens of CDYL mev/mev, 
mev/mev, and +I? mice. Panels on the left show percentage of IgM' cells. Panels on the 
right show percentage of I g M ~  cells that are CD43'1CD23-, an expression pattern 
characteristic of B-1 B cells. 
Total nucleated cell numbers in the spleen did not change significantly with age in 
CD5'- mev/mev, mev/mev, CDS4 +I? or +I? mice. The only significant change in 
percentages of spleen cell populations in CD5+ mev/mev with age was a decrease in the 
percentage of Mac-1' Gr-1- cells (p<0.05) in 15 - 18 wk-old mice in comparison to 9 - 
12 wk-old mice (data not shown). In contrast, several significant differences were seen 
when comparing spleens from 9 - 12 wk-old mev/mev mice to spleens of 15 - 18 wk-old 
mev/mev mice. Percentages of CD3' CD4' T-cells, Mac-1' Gr-1' cells and IgM' B220' B- 
cells were lower in 15 - 18 wk-old mev/mev mice when compared to 9 - 12 wk-old 
mev/mev mice (p<0.05), while the percentage of Terl19' cells was increased (p<0.01) 
(data not shown). 
Peripheral blood analysis 
Analysis of reticulocyte levels in peripheral blood using the Advia 120 
Hematology Analyzer showed a significant increase in reticulocyte percentages in CD5-'- 
mev/mev mice when compared to mev/mev mice (p<0.05) (Table 3.2). Reticulocyte 
percentages of both mev/mev and CD5" mev/mev mice were significantly higher than in 
wild type controls (p<0.05). Reticulocytes were also examined in smears of blood 
stained with NMB, as described (Figure 3.8). This data reflects the results found using 
the Advia 120 Hematology Analyzer. % 
Fignm 3.8. New methylene blue (NMB) staining for reticulocytes. Reticulocytes 
contain RNA, which precipitates in NMB and is stained blue. Reticulocytes have discernible 
blue granules (arrows). A manual reticulocyte count may be done by counting red cells in 
a smear of new methylene blue stained blood and calculating the percentage of total red 
cells that contain blue granules (reticulocytes). 
In contrast to reticulocyte numbers, peripheral blood red cell numbers were 
significantly reduced in both CD5-/ me'/mev and mev/mev mice in comparison to wild type 
(+/+ and +/?) controls at 9 - 12 wks of age ( ~ ~ 0 . 0 5 ) .  Although there was a significant 
increase in numbers of Ter-119' splenic nucleated erythroid cells in CDYL me'/mev mice 
in comparison to mev/mev mice (Table 3.1), there was not a corresponding increase in 
peripheral erythrocyte counts in CD5" mev/mev mice (Table 3.2). Moreover, there were 
no significant differences in peripheral erythrocyte or leukocyte counts between CD5'- 
mev/mev and mev/mev mice, although the average erythrocyte and leukocyte numbers as 
well as hematocrit percentages were slightly lower in CD5-I- mev/mev mice in comparison 
to mev/mevmice. Hematocrit percentages of mev/mev mice were lower on average than 
those of wild type (+/+ and +/?) mice, but the difference lacked statistical significance 
by a small margin (p = 0.055). Although the decrease in hematocrit percentages of CD5'. 
mev/mev versus mev/mev mice was also not statistically significant, CD5'- mev/mev mice 
did have significantly lower hematocrits than +/+ or +/? mice (p<0.0001). Erythrocyte 
mean cell volumes (MCV) did not differ significantly in any of the genotypes studied 
(data not shown). Peripheral blood leukocyte numbers were comparably increased in 
both CDFL mev/mev mice and mev/mev mice compared to wild type controls. The majority 
of these cells were monocytes and granulocytes (data not shown). There was no 
significant difference in either leukocyte or erythrocyte numbers in CD5-I- +/? mice 
versus wild type +/? mice. 
Table 3.2. Peripheral blood analysis of 9 - 12 wk-old CD5-'- mev/mev mice. 
B6;129 B6;129 CD5'- B6; 129 B6; 129 Cell Population 
mev/mev +/? CD5'- +/? 
mev/mev 
Erythrocytes 7.0 f 0.6 6.4 f 0.4 9.3 f 0.8 9.7 f 0.7 (x lo9 cellslml) 
Leukocytes 16.6 f 3.0 14.2 It 2.0 7.5 f 0.8 9.1 f 1.4 (x lo6 celldml) 
Hematocrit (%) 44.0 f 2.8 39.4 f 1.4 50.3 f 1.5 51.5 It 0.7 
Reticulocytes 
(as % of total 17.3 f 4.5 30.3 f 5.2* 2.9 f 0.1 2.8 f 0.2 
red blood cells) 
Data are expressed as stated f SEM (n >3 for reticulocyte percentages; n > 6 
for all other assays.) { *  indicates significant (p < 0.05) difference in peripheral 
blood cell populations between CD5'- mev/mev and mev/mev mice} 
Serum I? levels 
B-cells in mev/mev mice are hyperresponsive to stimulation through the B-cell 
receptor (BCR) (327). This hyperreactivity to BCR mediated signals in the absence of 
SHP-1 helps explain the otherwise counter-intuitive observation that serum levels of IgM 
and IgG in mev/mev mice are significantly higher than in wild type mice, whde their 
mature B-cell numbers are reduced. Since CD5'- mev/mev mice have significantly fewer 
B-cells than mev/mev mice, we assayed serum Ig levels in CD5" mev/mev and control mice 
(Figure 3.9). 
Figure 3.9. Serum immunoglobulin levels. Levels of serum IgM are significantly 
reduced in CD5-'- mev/mev mice in comparison to mev/mev mice (p<0.05). Absence of CD5 
did not result in a significant reduction of IgGl levels or IgG3 levels in CD~'- mev/mev 
mice in comparison to mev/mev mice. CD5" +/? mice showed a consistent reduction in Ig 
levels in comparison to wild type (+/?) mice. However, the difference was only 
statistically significant when comparing IgGl levels of CD54 +/? mice versus +/? mice 
with intact CD5. 
IgM levels were increased over 30 fold in mev/mev mice when compared with wild 
type (+/+ and +/me") mice. In C D ~ "  mev/mev mice, IgM levels were 70% lower than in 
mev/mev mice but still almost 10 fold higher than in wild type (+/+ and +/me") mice. 
Although previous reports have indicated that serum IgGl levels in C57BU6J-mev/mev 
mice are not significantly elevated over normal while serum IgG3 levels are significantly 
elevated in comparison with littermate controls (297), we found the opposite in our 
studies. IgGl levels were 2.5 times higher in the serum of mev/mev mice than in +/? 
litterrnates. These levels were lower in CD5" mev/mev mice than in mev/mev mice, but the 
change was not statistically significant. No significant variation was observed in IgG3 
levels between mutant and control mice. 
It is interesting to note that levels of IgGl were significantly reduced in CDSJ- +/? 
mice in comparison to +/? mice with a functional CD5 gene. Production of IgGl is T- 
cell dependent and CD5 expression by T-cells may be required to induce class switching 
or secretion of IgGl. Levels of IgM aid IgG3 were lower in CD5" +/? compared with 
+/? mice, but the differences were not statistically significant. 
Autoantibody assays 
To assess the presence of autoantibodies in CDS1 mev/mev and mev/mev mice, 
serum levels of anti-double stranded DNA (anti-dsDNA) and anti-histone antibodies were 
assayed by ELISA (Figure 3.10). Levels of these autoantibodies were elevated in the 
serum of both C ~ 5 - l -  mev/mev and mev/mev mice, when compared to wild type (+/+ and 
+/me? controls. In contrast to IgM levels, that were significantly reduced in CD5-I. 
mev/mev mice when compared to mev/mev mice, levels of both anti-dsDNA and anti- 
histone antibodies did not vary significantly between CD5-/- mev/mev and mev/mev mice. 
Levels of anti-histone and anti-dsDNA antibodies in CD5'- +/? mice showed no variation 
from +/+ and +/mev controls. 
B Anti-Histone 
Itdilution Itdilution 
Figure 3.10. Autoantibody determination by ELISA. Data is expressed as an average 
rate of substrate conversion in mO.D./min f SEM (n=4). 
Anti-phosphotyrosine western blotting 
Variation in levels of tyrosine phosphorylation between two experimental samples 
can indicate a possible alteration in cell signaling. In order to explore whether the 
pathological changes observed in CD5" mev/mev mice compared with mev/mev mice were 
accompanied by a difference in tyrosine phosphorylation, we examined total splenic 
protein by anti-phosphotyrosine western blotting (Figure 3.1 1). Spleen cell lysates were 
analyzed from mice at 12 - 15 wks of age as well as from mice at 5-8 wks (data from 
younger mice not shown). In mev/mev mice at 12 - 15 wks of age, there was an increase 
in tyrosine phosphorylation of proteins in the range of 28 - 45 kd. Highly 
phosphorylated proteins in this range were not seen in CD5'- mev/mev mice of any age, 
nor were they seen in younger mev/mev mice. 
Figure 3.11. Characterization of tyrosine phosphorylation of proteins in spleen cell 
lysates. Spleen cell lysates from male C57BU6J-CD5'- mev/mev and C57BU6J-mev/mev 
mice at 4 months of age were analyzed by SDS-PAGE/immunoblotting with anti- 
phosphotyrosine antibody. The positions of protein size markers (kDa) are indicated on 
the left. Arrows indicate bands that exhibit enhanced tyrosine phosphorylation in . 
C57BU6J-mev/mev mice in comparison to C57BU6J-CD5" mev/mev mice. 
Bone marrow macrophage cultures 
Further support of the hypothesis that CD5 on macrophages plays a role in the 
development of the macrophage pneumonia seen in mev/mev mice required confirmation 
of the presence of CD5 directly on macrophages. Takahashi et al. (328) reported 
development of CD5 expression on macrophages in cell cultures grown with CSF-1 or 
GM-CSF. To verify this, we established cultures of bone marrow cells from C57BU6J- 
mev/mev mice as well as from C57BU6J-+/? Controls and from C57BU6J-CD5-'- mice. 
Cultures were grown in the presence of either Rhu-CSF-1 or Rmu-GM-CSF. Adherent 
and non-adherent cells from cultures had similar cell surface marker expression profiles 
and were pooled for analysis. Flow cytometric analysis revealed that both C57BU6J-+/? 
And C57BU6J-mev/mev bone marrow contained cells that expressed CD5 after 7 days of 
culture with either 500 or 1000 units per rnl of CSF-1 or GM-CSF (Figure 3.12). There 
was no difference in percentages of CD5' cells with various amounts of cytokine, so 
results were pooled. Table 3.3 shows the mean results of three separate experiments. 
Following stimulation with GM-CSF, >90% of bone marrow cells that expressed CD5 
were found to co-express Mac-1. Bone marrow from CDSJ- mice grown under similar 
conditions, as expected, did not express CD5. Under all conditions, Gr-1 was expressed 
on 4 .3% of CD5' cells, and <0.9% of CD5' cells expressed CD19 or CD3. 
Table 3.3. Flow cytometry analysis of bone marrow cultures. 
- 
Cytokine CSF- 1 GM-CSF 
Genotype +/? mev/mev +/? mev/mev 
% of total cells that are 
CD5' 6.1 & 1.1 5.6 2- 0.9 4.0 + 2.7 9.7 + 2.7 
% of CD5' cells that are 
Mac-1' 
Data are expressed as a mean percent + SEM. (n > 5) (* indicates significant 
(p-cO.01) difference in % of CD5' cells expressing Mac-1 between mev/mev cultures 
grown with GM-CSF and +I? cultures grown with GM-CSF as well as +I? and mev/mev 
cultures grown with CSF-I.) 
eY 
mev/mev GM-CSF 
0 
F 
(Y 
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Figure 3.12. Expression of CD5 on bone marrow cells grown in culture for 7 days with 
1000 units per rnl GM-CSF. Top panel shows expression of CD5 on mev/mev cells, 
bottom panels shows lack of CD5 expression on CD5-'- cells. Dead cells were gated out 
using propidium iodide exclusion. Live cells were analyzed for CD5 expression. 
Numbers shown are percentages of CD5' cells. 
Discussion 
This study focused on the role of CD5 in imrnunopathologic changes in mev/mev 
mice. Absence of CD5 expression in mev/mev mice resulted in significantly increased 
lifespan and numerous phenotypic changes in comparison to mev/mev mice with an intact 
CD5 gene. Although a significant decrease in serum IgM levels was seen in CD5'- 
mev/mev mice, this was not associated with reductions in autoantibodies against dsDNA or 
histone proteins, two autoantibodies frequently elevated in mev/mev mice. The increased 
longevity of CD5" mev/mev mice was, however, associated with a marked delay in 
development of acidophilic macrophage pneumonia in these mice when compared to 
mev/mev mice. The reduced levels of macrophage infiltration in the lungs of CD5-'- 
mev/mev mice were associated with a significant decrease in myeloid cell numbers in the 
spleen. Although the reduced acidophilic macrophage pneumonia may be a consequence 
of altered interactions of B- or T-cells with myeloid cells due to the absence of CD5 on 
the surface of the lymphocytes, mature B- and T-cells are not necessary for the 
development of pulmonary inflammation in viable motheaten mice (329). Thus, the 
absence of CD5 function alone in either B- or T-cells would be unlikely to lead to such 
dramatic reduction of lung lesions as well as reduced myeloid cell populations in CD54 
mev/mev mice. 
Recently, CD5 has been found to be constitutively expressed on a population of 
macrophages in mev/mev mice (281). CD5' macrophages can be induced in the peritoneal 
cavity of wild type mice by treatment with high levels of GM-CSF. This cytokine is 
elevated in peritoneal fluid of mev/mev mice (328), and myeloid cells from mev/mev mice 
show enhanced signaling through the GM-CSF receptor (276). Our observation that 
CD5'- mev/mev mice have reduced numbers of splenic myeloid cells and less severe 
myeloid cell mediated pulmonary lesions compared with mev/mev mice may indicate a 
role for CD5 in response of cells to myeloid growth factors such as GM-CSF. We 
confirmed the development of CD5' macrophages in cultures of bone marrow from both 
mev/mev and wild type mice supplemented with either GM-CSF or CSF- 1, providmg 
support for the hypothesis that CD5 expression is involved with development or 
activation of macrophages through myeloid growth factor receptors. Although bone 
marrow cells from CD5-'- mice grown in culture with GM-CSF or CSF-1 lacked CD5 
expression, myeloid cell antigen (Mac-1 and Gr-1) expression profiles on these bone 
marrow cells were similar to cells from mice with an intact CD5 gene (data not shown). 
Additionally, no quantifiable or qualifiable differences were apparent in colony assays of 
bone marrow cells from CD5'- mev/mev mice or mev/mev mice grown in methylcellulose 
media with either CSF-1 or GM-CSF (data not shown). This data suggests that CD5 may 
play a role in later stages of myelopoiesis. 
For many years, the presence of a common progenitor for B-cells and 
macrophages has been suggested (330-333). Reports of biphenotypic Blmacrophage 
cells have appeared in current literature (334-336) and CD5' B-cells have been shown to 
develop macrophage characteristics (337,338), often in association with B-cell 
malignancy (339,340) (reviewed in (333)). It has been shown that treatment of wild type 
mice with GM-CSF resulted not only in an increase in numbers of CD5' macrophages, 
but also in an elevation in numbers of CD5' hematopoietic progenitor cells and CD5' B- 
cells (328), supporting the presence of a common precursor for CD5' (B-la) B-cells and 
CD5' macrophages. Lack of CD5 on biphenotypic Blmacrophage cells or on 
macrophages believed to have evolved from B-1 B-cells may contribute to the reduced 
severity of lung lesions seen in CD54 mev/mev mice in comparison to mev/mev mice. CD5 
expression may play a role in lineage commitment, possibly through altering responses to 
growth factors as suggested above. 
There are three reported ligands for CD5 that are expressed on B-cells. These 
ligands include CD72, CD5 ligand, and cell surface Ig. Interactions between CD5 and 
these ligands are thought to play a role in communication between T and B-cells. CD72 
is expressed constitutively on B-cells (341,342), while CD5 ligand (CDSL, gp40-80) is 
expressed on activated B lymphocytes in the spleen (343) and is constitutively expressed 
on peritoneal B-cells and B lymphoma cell lines (344). Poposil et al. (345) suggested 
that CD5 can also interact with certain sequences in the V, framework of cell surface Igs. 
Ligation of T-cell surface CD5 to gp40-80 on B-cells has been implicated in the 
stimulation of B-cell proliferation through the gp40-80 receptor (344). 
Until recently, CD5 ligands were reported to be present only on B-cells. 
However, several studies have now provided evidence that CD5 ligands are present on a 
variety of cell types in addition to B-cells, indicating that the interaction of CD5 with its 
various ligands may play a more diverse role in cellular communication than is currently 
thought. Agostini et al. reported the presence of CD72 on alveolar macrophages isolated 
from human sarcoidosis patients (346). A recombinant soluble protein based on the 
human CD5 extracellular region has been reported to bind to a variety of cells of myeloid 
as well as lymphoid origins (347), indicating the presence of a novel, widespread CD5 
ligand. Just as CD5'B-cells also express CD72, it is possible that a CD5 ligand is 
expressed on certain monomyeloid cells and that it may play a role in the activation of 
these cells through binding with CD5. Alternatively, interaction of CD5 with an 
unknown ligand could be involved in adhesion of monomyeloid cells to other cell types. 
The extracellular region of CD5 is closely homologous to that of CD6 (348), a scavenger 
receptor family member involved in cell-cell adhesion through its ligand, CD166 
(ALCAM) (349, 350). Interactions of CD5 with as yet unidentified ligands may be 
responsible for accumulation of macrophages in the lungs of motheaten mice due to 
dysregulated adhesion rather than solely dysregulated proliferation of pulmonary 
macrophages. 
Red cells and mature myeloid cells arise from a common multipotential precursor, 
termed CFU-GEMM based on the ability of these progenitor cells to form granulocyte, 
erythroid, monocyte, and megakaryocyte colonies in culture in response to the 
appropriate cytolunes. CFU-GEMMs can differentiate into either erythroid burst forming 
units (BFU-Es) in the presence of erythropoietin (Epo), or into granulocyte/macrophage 
colony forming units (CFU-GMs) in the absence of Epo but in the presence of myeloid 
growth factors such as GM-CSF. Spleens of mev/mevmice have previously been reported 
to contain high numbers of CFU-GMs in comparison to wild type mice, while the 
frequency of CFU-GMs in the bone marrow is similar in mev/mev and wild type mice 
(282). SHP-1 is involved in the negative regulation of Epo mediated signals (351). Both 
bone marrow and spleens of mev/mev mice contain increased numbers of erythroid 
precursors (CFU-Es) in comparison to wild type controls. CFU-Es from mev/mev mice 
are hyperresponsive to Epo and a subpopulation of mev/mev CFU-Es has lost their 
dependence on exogenous Epo (282). The increase in red cell precursors with a 
corresponding decrease in relative numbers of granulocytes in spleens of CD5" mev/mev 
mice versus mev/mev mice suggests the possibility that CD5 plays a significant role in the 
myeloid differentiation pathway in the absence of SHP-1. Dysregulated Epo signaling 
resulting from the absence of SHP-1 accompanied by insufficient myeloid growth factor 
mediated signals in the absence of CD5 could potentially explain the apparent shift from 
myelo- to erythropoiesis observed in CD5-l mev/mev mice in comparison to mev/mev mice. 
The lack of CD5 may cause changes in lineage commitment in the myeloidferythroid 
branch of cellular development as a result of a reduced response to myeloid growth 
factors. 
Although CD5 has been reported to be a negative regulator of signaling through 
both the T-cell receptor (290) and the B-cell receptor (352), earlier studies indicated a 
costimulatory role for CD5 in TCR signal transduction (3 53-355). Recently, additional 
studies have corroborated the reports of CD5 providing positive signals in both B- and T- 
cells, through a distinct cascade of second messengers including acidic sphingomyelinase 
and protein b a s e  C-4 (356). Our finding that proteins in the range of 28 - 45 kd 
showed increased phosphorylation on tyrosine residues in spleens of older mev/mev mice 
but not in CD5& mev/mev mice of the same age may provide additional evidence of a 
significant role in signaling for CD5. In the absence of the negative regulatory effects of 
SHP-1, the signals conveyed through CD5 may result in the phosphorylation of one or 
more novel signaling molecules in the 28 - 45 kd range. Identification of these 
molecules could help further elucidate the relationship between CD5 and SHP-1 and 
facilitate the resolution of the pathways in which these molecules interact. 
Clear examination of the role of CD5 in the development of viable motheaten 
pathological lesions is problematic on the B6;129 segregating background. A 
polymorphic variation between 129 and C57BU6J linked to the CD20 (Ms4a2) gene, 
which maps near the CD5 locus, has been shown to affect peritoneal B-1 cell populations 
(357). Although the phenotypic differences observed in B6;129-CD54 mev/mev mice in 
comparison to B6;129-mev/mev mice do not appear to be related to reduced B-1 cell 
numbers alone, the effect of strain specific polymorphisms is an important consideration 
in analyzing any targeted mutation on a segregating background. 
We have recently completed backcrossing of the CD5 mutation on to the 
C57BL16J background (to NlO) and have developed a colony of inbred C57BU6J-CD5'- 
mev/mev mice. Spleen cell lysates from C57BU6J-CD5-I-mev/mev and C57BU6J-mev/mev 
mice were utilized in the a-phosphotyrosine western blots shown in Figure 3.1 1. This 
experiment mirrored what was seen in extensive western blotting studies using B6; 129- 
CD5-I- mev/mev mice and B6;129-mev/mev mice. We are currently in the process of 
expanding our colony of C57BU6J-CD5'-mev/mev mice. With these mice, we will re- 
examine the imrnunopathologic changes observed in our previous studies using B6;129 
mice, as well as continue our investigation into the signaling alterations suggested by our 
reported western blotting results. Confirmation of the role of CD5 in immunopathologic 
changes in mev/mev mice using inbred C57BU6J-CD5-I-mev/mev mice will mitigate the 
complications of variability associated with background modifying genes and 
polymorphic diversity. 
Chapter 4 
GENERATION OF C57BLI6J MICE CARRYING A TRANSGENE FOR 
MACROPHAGE SPECIFIC EXPRESSION OF DOMINANT NEGATIVE SHP-1 
(C453S) 
Introduction 
The protein tyrosine phosphatase SHP-1, encoded by the hematopoietic cell 
phosphatase (Hcph) gene in mice (256,257), is a negative regulator of signaling through 
a number of hematopoietic growth factor receptors (258,276,280). Much of the 
knowledge of the function of SHP-1 has been gained through the study of motheaten and 
viable motheaten mice. As previously discussed, mice homozygous for either of these 
two recessive mutations exhibit severe immunodeficiency and autoimmunity, and die at 
an early age from inflammatory lesions, encompassing accumulations of macrophages 
and neutrophils in the lungs and elsewhere (250-253). These mice have many cellular 
abnormalities, including an increase in myelopoiesis (250,281) and multiple defects in 
lymphocyte development and function (282-285). 
One of the challenges in the study of SHP-1 using motheaten mice has been 
discerning the cell autonomous functional defects caused by the absence of SHP-1 from 
the secondary effects of macrophages and neutrophils resulting in disregulation of other 
cell populations. Previous attempts in our lab to transgenically rescue SHP- 1 expression 
in specific cell populations in motheaten mice have been constrained by findings that 
cells overexpressing SHP-1 in these transgenic animals have a selective disadvantage in 
proliferation compared with the dysregulated cell populations that lack functional SHP-1 
protein. Conversely, transgenic mice expressing a dominant negative or catalytically 
inactive form of SHP-1 under the control of cell specific promoters have been used 
successfully to study the effects of the absence of SHP-1 activity in vitro on individual 
cell types (358,359). 
Both me/me and mev/mev mice exhibit a marked expansion in numbers of 
monomyeloid cells. The importance of the SHP-1 phosphatase in regulating myeloid 
signaling pathways is evidenced by the severe inflammatory condition characteristic of 
motheaten mice. In order to dssect the cell autonomous defects caused by the lack of 
SHP-1 in macrophages, as well as to observe the effects of dysregulated macrophage 
populations on lymphoid and other myeloid cell populations, we created a mouse 
transgenic for macrophage-specific expression of a dominant negative form of SHP-1. 
SHP-1 mutant C453S cDNA has been used previously to produce a dominant 
negative protein in transgenic studies (358-360). The basis of this catalytically inactive 
dominant negative mutant was the identification of an essential cysteine residue at 
position 453 within the catalytic domain of SHP-1 (361). This essential cysteine, when 
mutated to a serine (Figure 4. I), results in a expression of a protein that can be recruited 
through its SH2 domains to imrnunoreceptor tyrosine-based inhibitory motifs (ITIMS), 
but has defective phosphatase catalytic activity. Binding of this inactive protein to SH2 
domain docking sites and substrates effectively blocks recruitment of endogenous wild- 
type SHP-1 (361), resulting in inhibition of SHP-1 function. 
NH2 - - COOH 
Figure 4.1. The dominant negative SHP-1 mutation C453S. The G + C transversion 
changes the essential catalytic cysteine (TCG), to a serine (TCC), inhibiting the 
phosphatase catalytic activity of the SHP-1 protein. This catalytically inactive form of 
SHP-1 competes for binding sites with wild type SHP-1, effectively reducing the activity 
of the wild type protein. 
To Qrect expression of the SHP-1 C453S mutant to macrophages, the promoter 
for c-fms was used. The c-fms gene encodes the cell surface receptor for macrophage 
colony stimulating factor (CSF-1) (362, 363). CSF-1 is a cytolune required for the 
proliferation and survival of cells in the mononuclear phagocyte lineage. Expression of 
the c-fms encoded CSF-1 receptor (CSF-1R) is regulated by tissue specific promoters 
(364). Expression occurs on macrophages as well as in the placenta during gestation. 
The promoter used in these studies induces macrophage specific expression of CSF-1R 
Materials and Methods 
Construction of SHP-1 dominant negative transgene for expression in macrophages. 
The pBluescript plasmid containing wild-type SHP-1 cDNA with a KT3 epitope 
tag and human growth hormone (hGH) poly A sequence driven by the CDl l b  promoter 
was a gift from Dr. Taolin Yi (Cleveland Clinic Foundation, Cleveland, OH). The 
macrophage specific c-fms (CSF-1R) promoter, (365) (in pBluescript) was a gift from Dr. 
Alessandra D'Azzo (St. Jude Children's Research Hospital, Memphis, TN). The SHP-1- 
KT3-hGH segment of the SHP-1 construct was excised using EcoH and was subcloned 
into a p138 plasmid linearized with EcoRZ. The c-fms promoter was excised from pBS 
with SpeZ and EagZ and ligated into the p138 plasmid containing the SHP-1-KT3-hGH 
construct, which was linearized with XbaZ and NotZ. The QuikChange Site-directed 
mutagenesis kit (Stratagene) was used to create a G to C transversion which changed the 
essential catalytic cysteine to serine, producing a construct that will express a putative 
dominant negative SHP-1 protein (359). Mutagenesis was performed according to 
manufacturers instructions using the following primers: (5'-CCG ATG CCA GCG CTC 
GAA TGC ACA ATG ATG G-3') and (5'-CCA TCA TTG TGC ATT CCA GCG CTG 
GCA TCG G-3'). 
Transgenic mice 
Transgenic C57BU6J mice were generated by standard methods by The Jackson 
Laboratory's microinjection service. Potential founders were screened for the transgene 
by PCR using primers specific for the second intron of the Hcph sequence (5'-TCC CTG 
GGA GCT TCC TGG CTC-3' and 5'-GGT GGG GTC CGA GCA GTT CAG-3'). 
Amplification with the endogenous SHP-1 gene yields a product of 494 bp, while 
amplification with transgenic SHP- 1 yields a product of 25 1 bp. Presence of the 
transgene was confirmed using primers for human growth hormone (5'-CAT CCC TGT 
GAC CCC TCC-3' and 5'-CTC CAA ACC ACC CCC CTC-3'). 
Hematoloy 
Blood was collected from the retro-orbital sinus with EDTA coated capillary 
tubes and placed directly into Isoton I1 diluent (Coulter). Hematologic values were 
determined using the ADVIA 120 hematology system (Bayer Corp, Tanytown, NY). 
Control C57BU6J mice were age and sex matched with each SHP-1 C453S transgenic 
animal tested. 
Culture of bone marrow macrophages 
To expand bone marrow macrophage populations for analysis, bone marrow plugs 
from femurs and tibias of transgenic and wild type mice were harvested by extrusion with 
cold HBSS (Sigma). Marrow plugs were dsrupted by passage through a 25g needle. 
The resulting single cell suspensions were washed 2x in sterile HBSS, counted with a 
model ZBI Coulter counter. Cells were resuspended in complete media (RPMI-1640; 
Sigma, containing 2 rnM L-glutamine, 10% FCS, 100 Ulml penicillin and 100 pglml 
streptomycin and 50 pM 2-P-mercaptoethanol) containing 500 unitslml recombinant 
human (rHu) CSF-1 (Cetus). A total volume of 5 ml CSF-1 supplemented medium 
containing lo6 cellslml was added to 25 cm2 tissue culture flasks. Cultures were 
incubated at 37°C in 5% CO, for 7 days with periodic changes of media, maintaining the 
appropriate CSF-1 concentrations. Cells were lysed in the flask for western blotting as 
described. 
Irnrnunoblotting 
Cultured cells were lysed for 30 minutes at 4°C in cold lysis buffer (50 mM Tris, 
pH 8.2, 150 mM NaCl, 1 % (Octylphenoxy)polyethoxyethanol (Igepal CA-630; Sigma), 
plus 1 tablet Complete, Mini Protease Inhibitor Cocktail Tablet w/EDTA (Roche 
Molecular Biochemicals) I 10 ml buffer. Cell lysates were clarified by centrifuging for 
20 min at 10,000g at 4" C. Protein levels were measures using the DC Protein Assay 
(Bio-Rad, Hercules, CA). 20 pg of each sample was resolved in a 12 % SDS-PAGE gel 
and transferred to a PVDF membrane (Millipore, Bedford, MA). The membranes were 
blocked in 5% dry milk overnight at 4" C, then incubated with rabbit anti-mouse SHP-1 
for 1-2 hours at room temp, with shaking. Membranes were then washed 3 X 5 min with 
TBS-T (TBS ~10 .05% Tween 20), incubated with HRP conjugated goat anti-rabbit ~ a b ~  
at RT for 30 - 60 min with shaking, then washed 5 x 5 min in TBS-T. Specific antibody 
signals were detected using an enhanced chemiluminescence kit (ECLp'"', Amersham 
Pharrnacia Biotech, Uppsala, Sweden). 
Results and Discussion 
The transgene was constructed as described (Figure 4.2). Sequencing from the 
carboxy terminal end of SHP-1 through to the hGH poly-A sequence revealed an error in 
the original construction of the CDl lb1SHP-1-KT31hGH plasmid. 
Figure 4.2. Construction of SHP-1 C453S transgene. Murine SHP-1-KT31hGH poly A 
was excised from pBluescript with EcoRI and cloned into p138, linearized with EcoRI. 
The CSF-1R promoter was excised from pBluescript with SpeI and EagI and was cloned 
into the p138 plasmid containing the SHP-1-KT3-hGH construct, which had been 
linearized with XbaI and NotI. Mutagenesis was performed on the final construct to 
change the essential catalytic cysteine to a serine (see Figure 4.1). The resulting 
transgene should express a dominant negative SHP-1 protein under control of the 
macrophage-specific promoter of CSF1-R (c-hs). 
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A fragment of SHP-1 consisting of base pairs 88 - 266 of the wild type protein was 
present at the carboxyl terminal end of the SHP-1 transgene, apparently in place of the 
KT3 epitope tag, since a KT3 sequence was not found. However, the full cochng 
sequence of the SHP-1 gene was present. Absence of the KT3 tag raises a number of 
challenges when trying to identify the transgenic protein in expression studies. Studies 
using dominant negative proteins that retain structural similarity to their wild type 
counterparts rely on an epitope tag to identify the transgenic protein by immunoblotting 
(359,360,366). The SHP-1 C453S transgenic protein differs from the wild type SHP-1 
protein by only one amino acid, and the c-fms promoter drives expression of the 
transgene in cells that normally exhibit significant expression of endogenous SHP-1. 
Without an epitope tag, demonstration of the successful expression of the transgene will 
rely on an increase in SHP-1 expression levels in macrophages, altered phosphorylation 
on tyrosine residues of SHP-1 substrates or functional studies. 
Transgenic mice were made by conventional methods, and founders were 
identified by PCR as described (Figure 4.3). From the first 34 possible founders, 4 
females were identified as transgenic. Of the following 71 possible founders, none tested 
positive for the transgene. A new batch of transgene DNA was submitted to the 
institutional microinjection service for generation of additional transgenic mice. The 4 
founders were mated to C57BU6J males. One female founder died unexpectedly at 12 
weeks of age, having produced no offspring. Founder #6 and founder #25 have produced 
offspring. The first litter of each of these founders contained transgenic mice. All 
existing transgenic mice, both founders and offspring from first litters, were bled from 
the retro-orbital sinus for peripheral blood analysis. 
Figure 4.3. PCR typing of SHP-1 C453S transgenic founders. Lane numbers correspond 
to both upper and lower panels. A) Typing using primers for SHP-1. Lanes 6 and 8 
show the intense 251 bp band indicating presence of the transgene. Lane 19: dH20, lane 
20: wild type DNA control. Amplification of a 251 bp band in wild type mice was 
unexpected, so transgene presence was confirmed by further typing with primers for hGH 
poly-A sequence. B) Typing with primers for hGH results in amplification of a 151 bp 
band in mice carrying the SHP-1 C453S trangene (Lanes 6 and 8). 
If the transgene was functional, and the SHP-1 C453S protein had a true dominant 
negative effect, one would expect to detect an increase in percentages of myeloid lineage 
cells in peripheral blood of transgenic mice. However, peripheral blood counts of 
transgenic and non-transgenic mice were not significantly different (Figure 4.4). There 
was no significant variation amongst mice carrying the transgene, so data from all 
transgene positive mice were pooled for comparison to wild type. 
" 
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Figure 4.4. Peripheral blood analysis of SHP-1 C453S transgenic mice vs. 
wild type C57BU6J mice. (n = 8) 
Macrophages containing numerous functional copies of the SHP- 1 C453S 
transgene should produce greater total levels of SHP-1 protein than wild type cells. To 
examine SHP-1 expression levels in the cell population to which transgene expression 
was directed, one transgenic offspring from founder #25 was sacrificed. Bone marrow 
was collected from femurs and tibias and cultured with CSF-1 to expand bone marrow 
macrophage populations. Analysis of these cultured cells by western blotting showed no 
increase in SHP-1 expression between SHP-1 C453S and wild type cells (Figure 4.5). 
These data suggest that the transgene is not functional in bone marrow macrophages 
grown in the presence of CSF-1. However, without an epitope tag to distinguish between 
SHP- 1 C453S and endogenous SHP- 1, it is possible that the transgene is being expressed, 
but does not result in a detectable increase in SHP-1 protein. However, there was also no 
detectable difference in tyrosine phosphorylation levels in SHP-1 C453S bone marrow 
macrophages versus wild type (Figure 4.6). This suggests that the presence of the 
transgene does not result in alteration of SHP-1 phosphatase function. 
Figure 4.5. Anti-SHP-1 western blot on bone marrow macrophage and spleen cell 
lysates from a SHP-1 C453S transgenic and control mouse. Lanes 1 & 2 contain lysates 
from bone marrow macrophages, lanes 3 & 4 contain total spleen lysates. Lanes 1 & 3 
are SHP- 1 C453S Tgn, lanes 2 & 4 are wild type. 2 pg of proteidlane. 
Figure 4.6. Anti-ptyr western blot on bone marrow macrophages of A) SHP-1 C453S 
transgenic mice and B) C57BU6J control mice. 
Preliminary studies of mice carrying a transgene for macrophage-specific SHP-1 
C453S expression do not confirm a functional effect of the transgene. Our collaborator 
(Dr. Taolin Yi) has recently developed a novel, more effective dominant negative SHP-1 
mutant. Although we will continue to expand the current founder colonies of SHP-1 
C453S, we will investigate the efficacy of this new dominant negative SHP-1 mutant for 
use in any future studies using a transgenic approach to alter SHP-1 function in a cell 
specific fashion. 
Chapter 5 
ESTABLISHMENT AND CHARACTERIZATION OF A NEW CELL LINE 
(MOS- J) FROM A SPONTANEOUS C57BLl6J MOUSE OSTEOSARCOMA.~ 
Abstract 
This chapter describes the establishment and characterization of an osteoblast-like 
cell line derived from a spontaneously occurring chondroblastic osteosarcoma in a 
C57BLJ6J mouse. The tumor line, MOS-J, forms solid tumors when injected 
intramuscularly into irnrnunocompetent syngeneic hosts, mimicking endochondral bone 
development. These transplantable tumors have the capacity to destroy and invade 
existing bone, and invade vessels in close proximity to the tumor. In culture, MOS-J 
cells form layers of pleomorphic cells with high mitotic activity. These cells have 
marked alkaline phosphatase enzyme activity and form calcified foci in vitro that stain 
with alizarin red. MOS-J cells also promote osteoclast development from normal bone 
marrow. These characteristics indicate the potential utility of the MOS-J osteosarcoma 
cell line as a model for the studies of human osteosarcoma and normal bone biology. 
Introduction 
In an effort to substantiate the role of SHP-1 as a tumor suppressor gene, our lab 
maintains aging stocks of +/me and +/mev mice, monitoring tumor incidence, and 
classifying and collecting samples of each neoplasm for analysis. A 25-month-old 
female +/mev mouse that was part of this study developed a firm, palpable mass in the 
right distal femur. The mass was identified histologically as a chondroblastic 
osteosarcoma, a rare tumor in mice (367,368). Preliminary investigation of this tumor 
did not support the hypothesis that it resulted from loss of SHP-1 heterozygosity. 
However, the cell line derived from this tumor may have significant value as a model of 
human osteosarcoma. 
Osteosarcoma is a malignancy of bone that commonly affects adolescents and 
young adults, accounting for approximately 20% of all primary malignant neoplasms of 
the bone in humans (369). Treatment often includes amputation of the affected area and 
adjuvant chemotherapy treatment. Despite aggressive surgical and medical therapies, 5- 
year survival rates range from only 10 to 60 %. 
Cell lines provide an important resource for investigating the pathophysiology of 
many types of cancers. These lines can be used for in vitro study of the biological 
behavior of cancer cells, including the basic mechanisms of oncogenesis, expression of 
growth factors and receptors and assessment of cell sensitivity to anti-neoplastic agents. 
Mouse cancer cell lines provide a valuable tool for in vivo study of in situ and metastatic 
tumor cell behavior following injection of the cells into immunocompetent syngeneic 
hosts or into immunodeficient mice. 
Here we describe an osteosarcoma cell line derived from a primary spontaneous 
mouse chondroblastic osteosarcoma (osteochondrosarcoma). This cell line has many 
characteristics of osteoblast-like cells, and may be a useful model for the study of both 
osteosarcoma and normal bone biology, both in vivo and in vitro. 
Modified from: Joliat MJ, Lyons BL, Umeda S, Lynes MA, Shultz LD. Establishment and 
characterization of a new cell line (MOS-J) from a spontaneous C57BU6J mouse osteosarcoma. In prep. 
Materials and Methods 
Source of cancer tissue 
The MOS-J (Mouse Qsteogenic Sarcoma - Jackson Laboratory) cell line was 
derived from a spontaneous chondroblastic osteosarcoma that arose in the right distal 
femur of a 757-day old female C57BU6J mouse heterozygous for the viable motheaten 
(Hcph"', hereafter abbreviated me3 mutation. The mouse was euthanized by CO, 
asphyxiation and the lesion was removed for examination. Minced pieces of the tumor 
were placed subcutaneously into ~ ~ ~ ~ l c ~ ~ ~ - ~ r k d c S ~ ~ % r k d c " ~ ~ ~  (hereafter called s id) 
mice. Additionally, portions of the tumor were disaggregated into a single cell 
suspension and cultured to establish the cell line. Other sections of the tumor were fixed 
for histological analysis as described below. 
Histopathology 
Tissues were fixed and demineralized in Bouin7s solution, or fixed in Fekete7s 
acid alcohol formalin and demineralized using Cal-EX decalcifying solution (Fisher 
Scientific, Fair Lawn, NJ). Tissues were then embedded in paraffin, sectioned at 6 pm 
and stained with Mayer's hematoxylin and eosin (H&E) for histological examination. 
Irnmunohistochemistry was carried out on serial tumor sections using mouse anti-alpha- 
smooth muscle actin (Sigma) for identification of vessel wall invaded by tumor cells. 
Non-specific staining was blocked on deparaffinized sections with peroxidase blocking 
reagent (DAKO). Tissue'sections were then incubated in primary antibody for 1 hour at 
room temperature in a humidified chamber, washed 3 x 5 minutes in PBS and then 
incubated with biotinylated secondary antibody against mouse IgG2a isotype for an 
additional hour. After another three 5-minute washes in PBS, tissues were incubated in 
avididhorseradish-peroxidase conjugate for 45 min, followed by an additional trio of 5- 
minute washes. Tissues were then incubated in diaminobenzidine (DAB) for 5 minutes at 
room temperature and washed in tap water for 5 to 15 min. Tissues were counterstained 
with hematoxylin, dehydrated in graded ethanol, cleared in xylene, and coverslipped with 
Permount (Fisher Scientific, Pittsburgh, PA). Processing of tissues was conducted by 
The Jackson Laboratory's Biological Imaging service. 
Establishment of the MOS-J cell line 
Immediately after removal of the original neoplasm, normal muscle, vascular 
tissue, fascia, and fat were removed from the specimen and discarded. Fractions of the 
tumor were minced and dispersed in complete media (cWMI: WMI-1640 (Sigma, St. 
Louis, MO) containing 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 pglml 
streptomycin and 50 pM 2-P-mercaptoethanol) in a 50 ml centrifuge tube. The resulting 
single cell suspension was seeded in 25 cm2 tissue culture flasks and incubated at 37' C 
in humidified 5% CO,. Culture medium was replaced twice a week until cells reached 
confluence. Cultures were exposed to trypsin-EDTA to release adherent cells from the 
surface of the flask, then were washed with fresh medium and subcultured at a density of 
2 x lo5 cellslml under similar culture conditions. 
Growth rate 
To determine the rate of cell growth, cells were plated at 5 x lo3 cells/cm2 in 35 
mm 6-well plates in minimum essential media containing 10% FBS. Each well had a 
growth area of 9.4 cm2. At 2 ,3 ,4 ,5 ,6 ,  and 7 days of incubation, cells were trypsinized 
and counted with a hemacytometer. Values are expressed as the mean number of cells f 
SEM from six wells. 
Cell culture characteristics 
Cells from the parental line were maintained in cRPMI. For studies of the 
characteristics of cells in culture, cells were seeded in a culture dish containing several 
glass coverslips. At 2, 5 and 9 days, a single coverslip was removed from the culture. 
Cells were fixed in methanol for 15 minutes, then stained with H&E, dehydrated through 
a series of ethanols to zylene and mounted on a slide with Permount (Fisher). 
Alkaline ~hosphatase detection in situ 
Cells were plated into 6-well culture dishes (Corning Costar, Corning, NY) at 5 x 
105cells per ml in a total volume of 6 rnl complete media per well. They were 
maintained in a humidified, 5% CO, incubator at 37' C for 72 hours. NM 3T3 cells were 
plated simultaneously and used as a negative control. After 72 hours at 37' C, the culture 
dishes were placed on ice. The medium was removed and the cells were washed twice in 
cold PBS. Cells were then fixed in the dishes for 20 min on ice with methanol. The 
methanol was removed and cells were washed twice in PBS. A BCIPINBT (5-bromo-4- 
chloro-3-indolyl phosphatelnitro blue tetrazolium) substrate kit for alkaline phosphatase 
was used (Zymed, San Francisco, CA) to detect alkaline phosphatase activity. The 
substrate solution was prepared as directed by the manufacturer and 5 ml was added to 
each well. Color development was allowed to occur for 5 - 10 minutes at room 
temperature, after which the substrate was removed and the cells were washed twice in 
distilled H,O. 
Alizarin red staining 
Cells were grown on coverslips in a culture dish for 30 days in cRPMI. Presence 
of calcium was assessed in cultured cells using a Dahl's method for calcium (370), with 
modifications. Briefly, cells were fixed for 15 min in methanol, then air-dried. Cells 
were then incubated for 10 minutes in a solution of 1% aqueous alizarin red, which had 
been adjusted to a pH of 6.4 with 0.1% ammonium hydroxide. Cells were rinsed three 
times in dH,O, counterstained in 0.2% light green for 15 seconds, and rinsed briefly in 
dH,O. Finally, cells were dehydrated through a graded series of alcohols to xylene and 
mounted using Perrnount (Fisher). 
Support of osteoclastogenesis 
C57BL16J bone marrow cells (2.5 x 104/cm2) were seeded simultaneously with 
tumor cells (1 x 104/cm2) in 8 well LabTek chambers and 6 well plates, in RPMI-1640 
(Sigma) containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 p g h l  
streptomycin and 50 pM 2-P-mercaptoethanol, supplemented with 10 nM/L 1-a-25 
dihydroxy (OH), Vitamin D, (Calbiochem, San Diego, CA). Cells were grown both with 
and without 500 U/ml recombinant human (RHu) CSF-1 (Cetus, Emeryville, CA) added 
to the medium to promote osteoclast growth. As a control, MOS-J cells and bone 
marrow cells were each grown alone with CSF-1. Cells were stained for tartrate resistant 
acid phosphatase (TRAP) using a leukocyte acid phosphatase kit (Sigma). 
Oncogenicity in mice 
Five male mice of each of the three strains (C57BL/6J, C57BU6J-Rag-I-'-, and 
N O D - R U ~ - ~ - ~ )  were injected in the quadriceps muscle with cultured tumor cells (1.3 x lo5 
cellsl0.lml sterile PBS). Growth was assessed by radiographic examination at 2 and 6 
weeks post inoculation. At seven weeks after injection, the primary mass was removed 
from two mice in each group by aseptic surgical amputation of the affected limb, as 
described below (Dr. B. Lyons). The remaining mice of each strain were euthanized and 
necropsied. Grossly evident nodules and selected organs were prepared for histological 
examination as previously described. Mice surviving amputation were assessed by 
radiographic examination for evidence of recurrence or metastasis. 
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Ultrastructural studies were performed on specimens obtained from transplanted 
neoplasms in BALBlcByJ-scid mice. Neoplasms were fixed in 2% glutaraldehyde in 0.1 
M cacodylate buffer for 60 minutes. Samples were rinsed in 0.1 M cacodylate buffer for 
15 minutes, then post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 15 
minutes, dehydrated in a graded series of ethanols (50 - loo%), then passed through 
polypropylene oxide as the intermediate solvent. Samples were re-embedded in 1:2 
propylene oxide 1 Epon mixture for 4 hours, exposed to a 1:3 propylene oxide 1 Epon 
mixture, then transferred to a conical Beem capsule. One hour later, the cells were placed 
in a dessicator and incubated overnight, then polymerized in a 60' C oven for 48 hours. 
One to two mm sections were cut and stained with Toluidine blue and ultrathin (70 - 
90nm) sections prepared from selected areas were mounted on copper grids. The sections 
were stained with aqueous uranyl acetate and Reynold's lead citrate and were examined 
using a transmission electron microscope (371). 
Amputation of affected limb 
Coxofemoral disarticulation (372) was performed to amputate the affected leg. 
Mice were anesthetized using Avertin (250 mgkg body weight). Muscle and skin layers 
were closed separately with absorbable sutures and the mice were kept in a quiet, heated 
environment and monitored until ambulatory. This procedure was conducted by a 
licensed veterinary surgeon, (B. Lyons, D.V.M.). The protocol was approved by the 
institutional Animal Care and Use Committee (ACUC). 
Results 
Histopathology of the original tumor 
The original tumor occurred spontaneously in the right &stal femur of a 25- 
month-old C57BU6J +/mev female mouse. The mass was lobular in shape, firm and pale 
white in color. Histological evaluation showed variably sized bundles and streams of 
closely packed undifferentiated spindled cells with discernable cell borders, containing 
numerous mitotic figures. These cells contained a moderate quantity of basophilic, finely 
fibrilar cytoplasm. Nuclei were pleomorphic, oval to elongate, containing course and 
finely granular heterochromatin. Scattered throughout the mass were areas of irregular, 
often interconnecting trabeculae of osteoid, generally contiguous with large areas of well- 
differentiated hyalin cartilage. Numerous multi-nucleated giant cells resembling 
osteoclasts were observed within the trabecular regions of the neoplasm. This tumor was 
interpreted to be a well-differentiated osteochondrosarcoma. No metastases were 
observed in lung, liver or other organs. 
Cell culture characteristics 
Growth rate and morphology of MOS-J cells were examined in culture. Figure 
5.1 shows the growth rate of MOS-J cells in MEM withlo% FBS. Under growth assay 
conditions in 9.4 cm2 wells, cells began to detach after 7 days. However, in 75 cm2 
culture flasks, cultures have been maintained successfully without passage for > 2 months 
with bi-weekly me&a changes. Cultured MOS-J cells form layers of large, closely- 
spaced, polygonal and elongated cells with random orientation, containing pleomorphic 
nuclei and abundant cytoplasm pigure 5.2). Multiple mitotic figures are present as well 
as individual cell necrosis characterized by pyknotic and karyorrhectic debris. 
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Figure 5.1. Growth rate of MOS-J cells in culture. 
Alkaline phosphatase activity 
Alkaline phosphatase activity is a characteristic feature of osteogenic 
differentiation of osteoblast-like cells (373). MOS-J cells showed marked alkaline 
phosphatase activity by enzyme cytochemistry (Figure 5.3 A). Negative control NIH 3T3 
cells under similar conditions showed no activity (data not shown). 
Alizarin red staining 
Alizarin red detects calcium deposition, which is a hallmark of ossification. Cells grown 
in culture contained numerous foci that stained positive for alizarin red (Figure 5.3 B, C). 
In the areas of darkest red staining, cells showed a circular pattern of aggregation. 
Osteoclast growth assay 
MOS-J cells promoted osteoclast growth in normal bone marrow cells (Figure 5.3 
D). TRAP-positive cells were present in cultures containing MOS-J cells with normal 
bone marrow cells. No quantifiable difference was seen in numbers of TRAP-positive 
cells in cultures grown with or without CSF-1. No TRAP positive cells were seen in 
CSF-1 supplemented cultures of tumor cells alone or bone marrow cells alone (Figure 5.3 
E, F). 

Oncogenici ty in vivo 
MOS-J cells form rapidly growing tumors when injected IM into 
immunodeficient mice as well as in immunocompetent syngeneic hosts. At two weeks 
post injection, radiodense lesions were visible in the muscle of all mice in the vicinity of 
injection. In some cases, osteolysis was evident in the existing bone adjacent to the 
lesion (Figure 5.4 B). At 7 weeks post injection, lesions were prominent, radiodense, and 
involved the bulk of the adjacent bone (Figure 5.4 C). In all cases, the injection 
ultimately resulted in one visible, palpable mass that was firm and occasionally multi- 
lobated. 
Histologically, the neoplasms were generally fairly well demarcated and non- 
encapsulated, with cells on the perimeter resembling periosteum. Spindle-shaped cells 
containing areas of osteoid trabeculae were interspersed with cartilaginous matrix (Figure 
5.5 A). Basophilic chondroblasts were visible in areas of cartilage production. Regions 
of well-mineralized neoplastic bone as well as reactive normal bone were present (Figure 
5.5 A, B). Lytic lesions were evident in existing bone (Figure 5.5 C). With IM injection, 
there was no evidence of metastasis, radiographically or histologically, even after 
amputation of the affected limb. However, there were multiple sites within indwidual 
tumors where neoplastic cells were seen in close proximity to or even penetrating or 
obliterating the vessel walls and growing into the lumen of vessels (Figure 5.5 D, E, F). 
Ultrastructural findmgs of transplanted tumors 
Tumor cells include large, irregularly shaped nuclei containing marginated 
chromatin and prominent nucleoli (Figure 5.6). The cytoplasm contained abundant rough 
endoplasmic reticulum (rER) and mitochondria. In some areas of the tumor, irregular 
electron dense granules resembling mineral deposits formed a halo-like pattern around 
the nucleus in the cytoplasm (Figure 5.6 A). Other areas of the tumor were characterized 
by an abundance of extracellular collagen fibrils (Figure 5.6 B). 





Discussion 
The MOS-J cell line was derived from a spontaneous chondroblastic 
osteosarcoma in a C57BL/6J +/mev mouse. The mev mutation disrupts the structural gene 
(Hcph) encoding SHP-1 protein tyrosine phosphatase, also referred to as hematopoietic 
cell phosphatase. The tumor derived MOS-J cell line was first examined for loss of 
heterozygosity of the wild type Hcph gene as part of a study of the putative role of Hcph 
as a tumor suppressor gene (254). If SHP-1 does indeed function as a tumor supressor 
gene, increased tumor rates would also be expected in heterozygous +/me or +/mev mice. 
Tumors would be expected to arise from cell types in which SHP-1 is known to function 
as a negative regulator, such as T, B, or myeloid cells, and these neoplastic cells would be 
expected to have deficient SHP-1 expression. The discovery of a firm tumor associated 
with the bone was unexpected in this study and was of particular interest. However, 
preliminary studies do not support the possibility that this tumor was caused by loss of 
expression of the SHP-1 protein (data not shown). Moreover, the cell line derived from 
this tumor has an osteoblast-like phenotype, and it has been shown that normal 
osteoblasts do not express SHP-1 (374). Nonetheless, many characteristics of the MOS-J 
cell line suggest that it may have utility in the study of bone biology as well as 
osteosarcoma biology and treatment. 
The MOS-J cell line has an aggressive phenotype characterized by unrestricted 
growth, but accompanied by numerous functional and histocytological features of normal 
osteoblasts. Alkaline phosphatase enzyme activity, ossification both in vitro and in vivo, 
and ability to promote osteoclast development in culture are all indicative of osteoblast- 
like function by the MOS-J tumor cells. These transplanted tumor cells mimic the 
process of endochondral ossification in vivo. Presence of basophilic chondroblasts and 
cartilaginous matrix within the tumor is similar to the histological variant of the human 
conventional osteosarcoma described as chondroblastic osteosarcoma. 
The derivation of this cell line from a spontaneous tumor in a C57BU6J mouse is 
a particular advantage over osteosarcoma cell lines derived from other species, less 
common mouse strains, or mice in which oncogenesis was promoted by insertion of an 
oncogenic transgene. These cell lines are often limited to transplantation into 
immunocompromised hosts. Certain transgenes that induce oncogenesis, such as the 
SV40 large-T antigen, can be immunogenic (375,376). Transplantation of cells derived 
from transgene induced tumors can result in tumor rejection by immunocompetent 
syngeneic hosts. Conversely, MOS-J cells may be transplanted, without rejection, into 
immunocompetent C57BU6J mice. Many strains of mice carrying targeted mutations or 
transgenes related to bone and cancer biology are maintained on the C57BU6J 
background (see (265)). Study of the behavior of MOS-J cells transplanted into mice 
bearing one or more of these mutations may provide insight into important biological 
interactions involved in tumor growth and metastasis or bone development and 
maintenance. 
MOS-J cells have many histocytological features of normal osteoblasts. They 
support osteoclast development when cultured with normal bone marrow, suggesting that 
these cells may be used in the study of intercellular interactions or the investigation of 
factors produced by osteoblasts that control osteoclast dfferentiation and activation. 
CSF-1 is essential for normal osteoclast development (377). The observation that MOS-J 
cells promote osteoclast formation in vitro without the addition of exogenous CSF-1 
suggests that the MOS-J tumor cells, like normal osteoblasts (378), secrete CSF-1. 
Experiments using other osteosarcoma cell lines have demonstrated that normal 
osteoblasts secrete Interleukin- 11 (IT.,- 11) (379), and that hepatocyte growth factor (HGF) 
can induce secretion of IL-11 from osteoblast-like cells (380). IL-11 stimulates 
TRANCE (TNF-related activation-induced cytokine) expression on osteoblasts (38 I), 
which is crucial to the stimulation of osteoclast differentiation and bone resorption (375). 
The MOS-J cell line may be a valuable tool in further understanding the intricate 
processes involved in skeletal development and restructuring. 
Although evidence suggests that the neoplastic characteristics of MOS-J cells are 
not associated with mutations in SHP-1, further molecular characterization of the MOS-J 
cell line has not been conducted. There are a large number of genetic mutations known 
to be associated with osteosarcoma in humans (for review, see (382)). Investigation into 
the genetic abnormalities existing in this line may identify novel mutations that lead to 
the development of osteosarcoma, or may reveal mutations already known to be 
associated with human osteosarcoma, providing a direct model for the study tumor 
development. 
Transplanted MOS-J cells have the capacity to infiltrate adjacent bone following 
intra-muscular injection, and appear to invade vessels at multiple sites within transplanted 
tumors. However, metastases have not been found in other organs. It has recently been 
shown that intra-tibia1 injection of the rat osteosarcoma cell line UMR 106-01 into 
athymic mice can result in lung metastasis where alternate methods of injection using the 
same cell line have failed to produce metastasis (383). A number of genetic variations 
have been associated with metastatic potential in an osteosarcoma model system (384). 
Isolation of a metastatic variant of MOS-J or development of an injection system that 
promotes metastasis of the transplanted tumor would enhance the value of this cell line 
for the study of genetic alterations associated with metastasis. However, we have 
assessed the metastatic potential of MOS-J cells following intra-tibia1 injection, and have 
found no evidence of metastasis. Despite the fact that a metastatic variant of MOS-J has 
not yet been identified, MOS-J cells may be valuable in comparative gene expression 
studies with osteosarcoma models that do show evidence of metastasis, such as the 
histologically and behaviorally distinct tumors that arise spontaneously in SV40 Tag 
transgenic mice (385,386). 
CONCLUSION 
Mice with spontaneous genetic mutations have provided crucial tools with which 
to develop our knowledge of normal and pathological biological processes. Studies using 
mice carrying the motheaten or viable motheaten mutations have advanced the 
understanding of numerous signaling pathways in the immune and hematopoietic 
systems. Recently, SHP-1 has received significant attention for its role in development 
of human cancers (261,262,264,387) and for its contribution to other diseases of 
hematological and immunological dysregulation (263,388). Continued investigation into 
the extensive signaling capacities of SHP-1 may lead to further insights into these 
diseases and into the complex physiological processes involved in maintaining 
homeostasis of the immune system. 
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